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SUMMARY
The formation of mammalian dendritic cells (DCs) is controlled by multiple hematopoietic transcription fac-
tors, including IRF8. Loss of IRF8 exerts a differential effect on DC subsets, including plasmacytoid DCs
(pDCs) and the classical DC lineages cDC1 and cDC2. In humans, cDC2-related subsets have been described
including AXL+SIGLEC6+ pre-DC, DC2 and DC3. The origin of this heterogeneity is unknown. Using high-
dimensional analysis, in vitro differentiation, and an allelic series of human IRF8 deficiency, we demonstrated
that cDC2 (CD1c+DC) heterogeneity originates from two distinct pathways of development. The lymphoid-
primed IRF8hi pathway, marked by CD123 and BTLA, carried pDC, cDC1, and DC2 trajectories, while the
common myeloid IRF8lo pathway, expressing SIRPA, formed DC3s and monocytes. We traced distinct tra-
jectories through the granulocyte-macrophage progenitor (GMP) compartment showing that AXL+SIGLEC6+
pre-DCs mapped exclusively to the DC2 pathway. In keeping with their lower requirement for IRF8, DC3s
expand to replace DC2s in human partial IRF8 deficiency.
INTRODUCTION
The hematopoiesis of dendritic cells (DCs) is controlled by a
network of transcription factors (TFs), including GATA2, SPI1
(PU.1), TCF4 (E2-2), ZEB2, IRF4, IRF8, and IKZF1 (IKAROS)
(Murphy et al., 2016; Collin and Bigley, 2018). Critical roles
have been demonstrated in humans for GATA2 (Dickinson
et al., 2014), IRF8 (Hambleton et al., 2011; Bigley et al., 2018),
and IKZF1 (Cytlak et al., 2018). DC potential traverses the pheno-
typic space of hematopoietic stem cells (HSCs), multipotent
progenitors (MPPs), common myeloid progenitors (CMPs),
lymphoid-primedmultipotent progenitors (LMPPs), and granulo-
cyte-macrophage progenitors (GMPs) (Lee et al., 2015, 2017;
Helft et al., 2017). Single-cell cloning experiments demonstrate
oligo- and unipotent differentiation pathways and highlight crit-
ical interactions between TFs such as SPI1 (PU.1) and IRF8 in
priming and directing DC development (Lee et al., 2017; Velten
et al., 2017; Giladi et al., 2018).
Functionally distinct populations of DCs arise directly from he-
matopoiesis itself (Lee et al., 2017; See et al., 2017; Villani et al.,
2017). Plasmacytoid DCs (pDCs) are distinct from myeloid or
classical DCs (cDCs), comprising two subsets, cDC1s and
cDC2s, evolutionarily conserved across mammalian species
(Guilliams et al., 2016; Granot et al., 2017). DC potential is found
in CD123+ regions of human GMPs (Lee et al., 2015; Helft et al.,
2017), wheremost cells have unipotential fates for pDCs, cDC1s,
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or cDC2s (Lee et al., 2017). These observations are more consis-
tent with contemporary lineage-primed models of hematopoie-
sis in which cell fate specification occurs in the early stem and
progenitor cell compartments and development progresses
along increasingly stable unipotent trajectories (Naik et al.,
2013; Notta et al., 2016; Velten et al., 2017; Giladi et al., 2018;
Laurenti and Go¨ttgens, 2018). However, the phenotypic identi-
ties of GMPs that contain discrete DC potentials leading to
pDCs, cDC1s, and cDC2s in human have not been described.
Human cDC2s, hereafter referred to as CD1c+ DCs, comprise
two subpopulations in peripheral blood (PB), one closer in gene
expression and function to cDC1s and the other to monocytes
(Schrøder et al., 2016; Yin et al., 2017; Alca´ntara-Herna´ndez
et al., 2017; Korenfeld et al., 2017; Villani et al., 2017). However,
it is not known if both types of CD1c+ DC arise from distinct line-
age trajectories, differentially regulated by TFs, or whether they
represent two alternative transcriptional states of a common
lineage originating from the CD123+ GMP.
IRF8 plays a major role in DC development. In mice, it is
required for normal development of cDC1s and pDCs (Tailor
et al., 2008; Grajales-Reyes et al., 2015; Sichien et al., 2016).
Acting at multiple stages, it balances neutrophil, monocyte,
and DC fate in combination with the TFs CEBPa and PU.1 (Lee
et al., 2017; Giladi et al., 2018; Becker et al., 2012; Kurotaki
et al., 2014). In common with other TFs regulated by super-en-
hancers, IRF8 effects are dose-dependent (Afzali et al., 2017).
We have previously described two humans with bi-allelic IRF8
mutations (IRF8K108E/K108E and IRF8R83C/R291Q) with a complete
absence of monocytes and DCs (Hambleton et al., 2011; Bigley
et al., 2018). K108Emutation results in loss of nuclear localization
and transcriptional activity, concomitant with decreased protein
stability (Salem et al., 2014). R291Q is orthologous to R294,
mutated in the BXH2 Irf8-deficient mouse. R83C shows reduced
nuclear translocation, and neither R291Q nor R83C is able to
regulate the Ets-IRF composite element or interferon (IFN)-stimu-
lated response element, althoughR291Q retains BATF-JUN inter-
actions in vitro (Bigley et al., 2018). The heterozygous parents of
these individuals, togetherwith a new kindred affectedby an inter-
mediate autosomal-dominant phenotype caused by a frameshift
at V426, provide an allelic series of IRF8 activity.
In the present study, we use in vitro cultures, single-cell anal-
ysis, and the series of human IRF8 variants to resolve two
discrete pathways of DC development differentially dependent
upon IRF8, each forming distinct subsets of the CD1c+ DC pop-
ulation. The IRF8hi pathway is linked to a classical pathway
shared by cDC1s and pDCs. The IRF8lo pathway is linked to
the development of monocytes.
RESULTS
CD1c+DC Heterogeneity Is Evident in Human Bone
Marrow
Wefirst sought to define CD1c+DC heterogeneity in healthy con-
trol (HC) human PB by conventional flow cytometry. This re-
vealed differential expression of monocyte-related antigens
CD14 and CD163 and lymphoid-associated antigens CD5 and
BTLA (Figures 1A, 1B, and S1A) within the CD1c+ DC population.
CD14 and CD5 expression marked the poles of a phenotypic
continuum and CD163+BTLA and CD163BTLA+ populations
were identifiable within the CD14CD5 gate. Notably, CD14
expression on CD14+CD1c+ DCs is at least 1 log lower than on
classical monocytes (Figure S1B), which were excluded by
CD88 expression. This continuum was mirrored at the transcrip-
tomic level (Figure 1C) and was concordant with the differential
expression of genes distinguishing DC2s from DC3s and DC3s
frommonocytes, as described previously (Villani et al., 2017; Fig-
ures S1C and S1D; Table S1). In response to Toll-like receptor
(TLR) stimulation, all fractions of CD1c+ DCs were able to elabo-
rate interleukin-12 (IL-12), in contrast to monocytes. However,
the monocyte-related cytokines IL-1b and IL-10 were produced
by CD14+CD1c+ DCs (Figures 1D and S1E).
CD5+ and CD14+ CD1c+ DC subsets, with differential CD163
expression, were present in HC spleen and dermis (Figures 1E,
S1F, and S1G). However, BTLA expression was much lower in
spleen and only just detectable in dermis (Figures 1E and S1H).
Bone marrow (BM) also contained homologous populations,
although BTLA was not well expressed in this tissue (Figures 1F
and S1F–S1H). To simultaneously interrogate PB and BM, the
panel was extended using mass cytometry (cytometry by time
of flight [CyTOF]). CD1c+ DCs were delineated by the expression
Figure 1. CD1c+ DC Heterogeneity Is Evident in Human BM
(A) Flow phenotyping of CD1c+ DCs from HC PB mononuclear cells (PBMCs) (representative example of n = 22), distinct from SIRPACD141+ cDC1s,
CD123+CD303/4+ pDCs, and CD88+monocytes (Mono). CD14+CD163+BTLA (orange), CD14CD163+BTLA (light orange), CD163BTLA+CD5 (light red), and
CD163BTLA+CD5+ (red) CD1c+ DC subsets are indicated.
(B) 3D representation of CD14, CD5, and BTLA expression (flow cytometry) across the CD1c+ DC population. Heatmap shows expression of CD163.
(C) PCA of NanoString gene expression profiling of fluorescence-activated cell sorting (FACS)-purified DC subsets from n = 3 HC PBMCs. CD1c+ DCs were
purified based on their expression of CD14, CD5, and BTLA (A).
(D) Intracellular flow analysis of in vitro cytokine elaboration (percentage of positive cells) by PB monocytes (black) and CD1c+DC subsets CD14+ (orange),
CD14CD5 (gray), and CD5+ (red) from n = 9HCdonors in response to 14-h stimulation with TLR agonists (CpG, poly(I:C), CL075, and lipopolysaccharide [LPS]).
p values were derived from paired two-tailed t tests; *p < 0.05; **p < 0.01; ***p < 0.005. Bars show mean ± SEM, and circles represent individual donors.
(E and F) Representative examples of the flow profiling of DC subsets in human spleen (n = 3), dermis (n = 3) (E) and BM (n = 13) (F), gated as in (A). Histograms
show CD163 and BTLA expression on CD14+ (orange), CD5+ (red) and CD14CD5 (gray) CD1c+ DCs.
(G) tSNE visualization of the expression of TFs and surface markers across HC PB and BM lineage(lin, CD3,19,20,56,161)-HLA-DR+ cells by CyTOF analysis.
Black gates indicate the CD1c+DC population distinct from CD88+monocytes, CLEC9A+cDC1 and CD303+pDC. Red and orange gates indicate expression of
lymphocyte- or monocyte-associated antigens, respectively.
(H) Hierarchical clustering of single-cell transcriptomes of mature DCs from BM using all protein-coding, non-cell-cycle genes. Marker genes were identified
within SC3 with parameters p < 0.01, area under the receiver operating characteristic curve (AUROC) > 0.85; cluster 1, pDCs (GZMB, JCHAIN); cluster 2,
monocytes (S100A8, VCAN); cluster 3, CD14+ DC3s (HLA-DPB1); cluster 5, cDC1s (CD59). The top rows show fluorescence intensity of surface antigens
(‘‘Antigens’’) from index-sorted cells, and ‘‘Phenotype’’ denotes their classification defined by surface markers.
See also Figure S1.
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of CD1c, CD2, FcεR1A, and IRF4, distinct fromCD88+monocytes
and other DC subsets (Figures 1G, S1H, and S1I; Table S2). In
both tissues, the CD5+ pole was apposed to a small SIGLEC6+-
AXL+ population (both BTLA+ in PB), while the CD14+ pole ex-
pressed monocyte-related antigens CD11b and CD36.
Index-sorted single-cell RNA sequencing (scRNA-seq) and
unsupervised hierarchical clustering of mature DCs from HC
BM confirmed that CD1c+ DCs were heterogeneous and tran-
scriptionally distinct frommonocytes (Figures 1H and S1J; Table
S3). CD14+CD1c+ DCs (cluster 3, high HLA-DPB1) clustered
separately from CD14bright monocytes (cluster 2, marked by
S100A8, VCAN) but shared some monocyte-related transcripts.
In contrast, clusters 6–8, encompassing CD5+CD1c+ DCs,
shared features with cDC1s (cluster 5, CD59).
These experiments defined a set of antigens marking hetero-
geneity of CD1c+ DCs in multiple tissues. Depending on the
context, one or more antigens may be used to bisect the popu-
lation into DCs enriched for lymphoid- (CD5 and BTLA) or mono-
cyte-related (CD14 and CD163) markers. For consistency with
recent literature, we will refer to CD163 (CD5+ and CD5) cells
as DC2s (BTLA+ in PB) and CD163+ (CD14+ and CD14) cells as
DC3s (BTLA in PB) (Figure S1M). The presence of a discrete
population of DC3s in BM is consistent with a direct hematopoi-
etic origin rather peripheral conversion of monocytes.
CD14 Expression Distinguishes Heterogeneous CD1c+
DC Subsets Generated In Vitro
The generation of CD1c+ DCs subsets has not been previously
demonstrated by in vitro culture. To probe this potential in human
progenitor and precursor subsets we tested a system containing
stem cell factor (SCF), FLT3 ligand (FL) and granulocyte-macro-
phage-colony-stimulating factor (GM-CSF) with Csf1/ OP9
stromal cells to prevent overgrowth of monocytes (Nakano
et al., 1994). It was possible to differentiate all primary DC sub-
sets and some CD14+ monocytes in this system (Figures 2A
and S2A). The output was analyzed by at least two surface
markers per subset. CD1c+ DCs were distinguished from mono-
cytes by their expression of CD1c and CD2 and lack of CD88
(Figures 2A and 2B). Within the CD1c+DC compartment,
CD163 was exclusively expressed by CD14+ cells, while CD5+
cells were contained within the CD14 population. In this sys-
tem, CD14 expression defined populations corresponding to
PB DC2s (CD14CD163) and DC3 (CD14+CD163+) (Figures
2A and 2B). Culture-derived DCs and monocytes retained
appropriate expression of TFs IRF4 and IRF8 (Figure 2C).
Two observations suggested that CD1c+ DC subsets were
generated independently of monocytes and of each other. First,
CD1c+ DCs appeared early, ahead ofmonocytes (Figure 2D). Sec-
ond, ex vivo PB CD1c+ DC subsets and monocytes remained sta-
ble in culture for 7 days and did not interconvert (Figures 2E and
S2B). Although some PB DCs gained CD14 expression in vitro,
this was restricted to CD14 (CD163+BTLA) DC3s (Figure 2F).
Thus, in vitro, CD14 functions as a more inclusive marker for DC3
than in fresh PB, where it marks only the pole of this phenotype.
There was some loss of CD5 expression on DC2s in vitro, but this
did not hamper the separation of DCs and monocytes by CD88,
CD1c, CD2, and CD163, which all remained stable (Figure 2E).
The identity of in-vitro-generated DC2s, DC3s, andmonocytes
generated in this system was validated by transcriptomic and
functional analyses. Principal-component analysis (PCA) of
NanoString gene expression data showed that in-vitro-gener-
ated CD14 DC2s and CD14+ DC3s were appropriately polar-
ized relative to cDC1s and monocytes (Figures 2G and S2C).
Key signature transcripts of sorted PB DCs were also expressed
in the corresponding cultured cells, including BTLA, CD5, and
HLA-DOB in DC2s, IL1B in DC3s, and ZBTB16 in monocytes
(Figure 2H). Genes defining DC2s, DC3s, and monocytes (Villani
et al., 2017) were appropriately enriched in culture-derived pop-
ulations (Figures S2D and S2E), which also generated similar
cytokine profiles to fresh PB DCs and monocytes on TLR stimu-
lation (Figures 2I and S2F).
High IRF8 Expression Defines LMPP-Associated DC
Progenitors
This in vitro culture system was used to map DC potential in
sorted fractions of human BM. In describing immature cells,
Figure 2. CD14 Expression Distinguishes between CD1c+DC Subsets Generated In Vitro
(A) Gating strategy used to identify DCs and monocytes generated from HC BM CD34+ progenitors at day 21 (D21) of culture on OP9 in the presence of SCF, FL,
and GM-CSF. A minimum of two antigens was used to define the following populations: CD141+CLEC9A+ cDC1s, CD123+CD303+CD304+ pDCs, CD2+CD1c+
DCs encompassing CD14+ and CD5+ populations, and CD14+CD1cCD2 monocytes.
(B) Flow analysis of the expression of population-specific markers across in vitro-generated monocytes (black), CD14+ (orange), CD5+ (red), or CD5 (pink)
CD14CD1c+ DCs as defined in (A).
(C) Intracellular flow evaluation of the expression of IRF4 and IRF8 by PB and culture-derived monocytes and DCs, gated as shown in Figure 1A and (A),
respectively.
(D) Kinetics of DC culture output over 21 days plotted as the number of DCs or monocytes generated per CD34+ progenitor. n = 6 donors with minimum n = 3 at
each time point. Dots and bars show mean and SEM.
(E) Flow analysis of the expression of population-specific markers by FACS-purified PB monocytes and CD1c+ subsets at day 7 of culture.
(F) Flow analysis of CD14 expression by FACS-purified PB CD1c+subsets at day 7 of culture. Histogram shows a representative example from n = 7 (CD14DC3
andCD5DC2) or n = 5 (CD5+ DC2) HC donors, summarized in the graph. Bars representmean ± SEM. Circles represent individual donors. ***p < 0.005 by paired
two-tailed t test.
(G) PCA of NanoString gene expression of FACS-purified PBDCs (‘‘PB’’) (n = 3) and DCs derived fromBMCD34+ progenitors at D21 of culture (‘‘C’’; black outline)
(n = 3) after removal of a ‘‘culture signature’’ generated by pairwise comparison of all PB versus all culture-generated cells.
(H) Heatmap of Z scores of differentially expressed signature genes (NanoString) derived from pairwise comparisons of PB CD1c+ DC subsets and monocytes,
shown next to the Z scores of expression of the same genes by culture-derived CD14 and CD14+ DCs and monocytes.
(I) Intracellular flow analysis of in vitro cytokine elaboration (percentage of positive cells) in response to TLR agonists, as described in Figure 1D, by CD14+CD1c
monocytes (black bars), CD14+ DC3s (orange), and CD14DC2s (red) generated from n = 4 BMCD34+ progenitors at day 21 of culture. p values from paired two-
tailed t tests; *p < 0.05; **p < 0.01; ***p < 0.005. Bars show mean ± SEM.
See also Figure S2.
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the terms ‘‘progenitor’’ and ‘‘precursor’’ refer specifically to
CD34+ and CD34neg-int populations, respectively (Table S4). Hu-
man DCs have previously been derived from classical myeloid
progenitors (CMPs and GMPs), LMPPs, and CD123+ fractions
of the GMP, which were included here for comparison. HSCs
and MPPs were identified in CD38lo gates (Figure 3A). CD10+
MLP and CD10CD117+LMPP fractions were selected from
the CD38loCD45RA+ population. From the CD38hi fraction were
isolated CD45RACMP megakaryocyte-erythroid progenitors
(MEPs) and CD45RA+ GMPs; CD10+ B and natural killer (NK)
cell progenitors (B/NKs) were excluded. Within the GMP gate,
surface expression of CD123 correlated with intracellular
expression of IRF8, so CD123 negative-low, low, and intermedi-
ate fractions were gated prospectively for differentiation studies
(Figures 3B and S3A). Myeloid antigens CD33 and CD117 were
expressed by a subset of CD123neg-lo GMPs (GMP33+);
CD33CD117 cells (GMP33) within this gate were analyzed
separately (Figure 3A). CD33 was also expressed by cells in
the CD38+CD45RA compartment, known to contain CMP and
MEP populations. CD33+ CMPs, with low expression of
CD123, were sorted for comparison with CD33 cells, predicted
to contain mostly MEPs (Figure S3B).
DC potential was found in CMPs, GMPs, and LMPPs (Figures
3C and S3C–S3E). pDCs, cDC1s, and DC2s mapped to LMPPs
and CD33, CD123lo, and CD123int fractions of GMPs. DC3 po-
tential was principally found in the CMP andCD123neg-loGMP33+
fractions (Figure 3C). Although therewas incomplete dissociation
of DC2 from DC3 potential using this apposed-gate strategy, the
output ratio of DC2s toDC3s rangedwidely, from17.65 in LMPPs
to 0.45 inCD33
+
CMPs (FigureS3D). The relatively higher produc-
tion of pDCs, cDC1s, and DC2s in the CD33, CD123lo, and
CD123int GMP fractions was associated with increasing expres-
sion of IRF8 protein (Figures 3B, 3C, and S3A). In contrast, DC3
potential localized predominantly to IRF8lo progenitor fractions.
Transcriptional programming of the phenotype and culture po-
tential seen in bulk populations was probed by index-sorted
scRNA-seq of BM progenitors. Approximately equal numbers
of CD34+ progenitors (excluding lineageloCD10+ B/NK progeni-
tors) were sorted from the quadrants defined by a bivariate
plot of CD45RA and CD38 (Figure S3F). scRNA-seq was per-
formed with a modified SmartSeq2 protocol (Picelli et al.,
2014). 262 out of 399 cells expressing 12,406 protein-coding
genes passed quality control (QC) filters and cell-cycle-related
transcripts were removed (STAR Methods; Table S3). The
computational pipeline, including dimensionality reduction, hier-
archical clustering, and trajectory analyses, was unbiased and
driven solely by gene expression data. Clusters were then map-
ped to cell-surface phenotype from indexed flow data.
Hierarchical clustering of cells within the GMP compartment
revealed close relationships among CD33, CD123lo, and
CD123int fractions of GMPs that formed a single IRF8hi cluster
(cluster 4) distinct from IRF8lo GMP33+ clusters associated
with monocyte (cluster 1), granulocyte (cluster 2), and early
myeloid gene expression (LYZ, ELANE, and MYC, respectively)
(Paul et al., 2015; Wilson et al., 2004; Figures 3D and S3G–S3I).
Broadening the analysis to include scRNA-seq of HSCs,
MPPs, MEPs, CMPs, LMPPs, and MLPs (Figure S3J), a single
cluster contained cells with in vitro pDC, cDC1, and DC2 poten-
tial (cluster 8), marked by the expression of the DC-related genes
TCF4 and RUNX (Cisse et al., 2008; Satpathy et al., 2014). Clus-
ter 8 was adjacent to LMPPs (clusters 9 and 10) but remote from
CMPs and GMP33+ (clusters 1 and 2) containing in vitro mono-
cyte and DC3 potential.
Indexed phenotypes overlapped closely with cluster assign-
ment visualized on t-distributed stochastic neighbor embedding
(tSNE) plots (Figures 3E and 3F), although heterogeneity for
DC-progenitor-related transcriptomes was revealed within
phenotypic LMPPs. Phenotypic CD33+ CMPs and GMPs also
contained two clusters associated with monocytic or granulo-
cytic gene expression, respectively (cluster 1, marked by LYZ
and CSF1R; and cluster 2, marked by ELANE, CALR, and
FAM46A) (Paul et al., 2015; Pellin et al., 2019; Figure S3J). The
Figure 3. High IRF8 Expression Defines LMPP-Associated DC Progenitors
(A) Flow gating strategy used to define and FACS-purify components of the CD34+ lin(CD3,14,16,19,20,7) compartment of human BM. HSC, hematopoietic
stem cell; MPP, multipotent progenitor; MEP, megakaryocyte-erythroid progenitor; MLP, multilymphoid progenitor; LMPP, lymphoid-primed multipotent pro-
genitor; CMP, common myeloid progenitor; GMP, granulocyte-macrophage progenitor.
(B) Heatmap of intracellular IRF8 protein expression across CMP and GMP as defined in (A) (gate 1).
(C) Monocyte and DC subset output from purified BMCD34+ populations at day 14 of culture gated as in Figure 2A. Populations were quantified as percentage of
the total cells captured by all DC and monocyte gates. Absolute output is shown in Figure S3C. Bulk CD34+ (22 experiments from 13 donors: 22;13); CMP (7;5);
GMP33+ (7;6); LMPP (7;6); GMP33 (6;6); GMP123lo (3;3); GMP123int (8;7) (Table S4). Bars represent mean + SEM, and circles represent individual experiments.
Significant differences in the proportional output of DC2s versus DC3s are indicated in red; *p < 0.05; **p < 0.01; ****p = 0.0001 (paired two-tailed t tests).
(D) Unsupervised hierarchical clustering of transcriptomes of single cells within the GMP index-sorting gate, using all protein-coding, non-cell-cycle genes,
independent of surface antigen expression. Marker genes for four clusters identified within the single-cell consensus clustering 3 (SC3) tool (p < 0.1, AUROC >
0.75) and IRF8 are displayed. The top rows show fluorescence intensity of surface antigens from index-sorted cells. Flow annotation (‘‘Flow annot’’) denotes the
classification of cells by their surface phenotype (Figures 3A and S3F).
(E–G) tSNE visualization of the first 10 principal components (25% of total variance) of the transcriptomes of 262 CD34+ progenitor cells, independently of their
surface phenotype. tSNE plots are shown annotated by (E), gate of origin from index-linked flow (Figure S3F), or (F), 10 clusters from hierarchical clustering
(Figure S3J), Heatmaps (G) show flow surface antigen expression (‘‘SA’’) and log2 expression of key DC TFs, IRF8, TCF4, SPIB, and SPI1(PU.1), displayed across
the tSNE plot (E and F). Black circles represent regions of high (‘‘A’’) or low (‘‘B’’) IRF8 expression.
(H and I) Diffusion map using all protein-coding, non-cell-cycle genes. (H) The key specifies the designated cluster color, identity, and cluster number from
Figure S3J. (I) IRF8 expression. Diff Comp, diffusion component.
(J) Violin plot of differential IRF8 expression (log2) in progenitor clusters 5 (HSCs and MPPs), 1 (monocyte enriched), and 8 (DC related). **p = 0.001 by Mann-
Whitney U.
(K) Median fluorescence intensity (MFI) of intracellular IRF8 by flow analysis across gates identifying HC BM CD34+ HSCs and CD123neg-lo CD33+ and CD123int
GMPs (n = 4) as defined in (A). *p = 0.028 by Mann-Whitney U.
See also Figure S3.
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majority of early progenitors did not express IRF8, but two sig-
nals were present: high expression associated with the DC clus-
ter 8 and lower expression associated with the GMP33+ mono-
cytic cluster 1. The IRF8hi region (‘‘A’’; Figure 3G) was also
marked by high CD2, TCF4, and SPIB, and the IRF8lo region
(‘‘B’’; Figure 3G) expressed high CD33 and SPI1 (PU.1). A and
B are linked to DC precursor populations as described subse-
quently in Figure 4.
Diffusion mapping represented clusters 1 (monocyte en-
riched), 6 (MEPs), and 8 (DCs) as divergent trajectories (Fig-
ure 3H; Data S1). Clusters 9 and 10 (LMPPs) were located at
the root of the DC trajectory and cluster 7 (early myeloid) at the
root of the monocyte-gene enriched path. IRF8 gene expression
was statistically higher in the DC (cluster 8) compared to mono-
cytic (cluster 1) trajectory (Figures 3I and 3J), as was the protein
in corresponding indexed GMP populations (CD123int versus
CD33+) (Figure 3K).
Taken together, the in vitro culture data, scRNA-seq analysis,
and flow phenotypes are consistent with the transition of pDC,
cDC1, and DC2 potential through LMPP phenotype space to
CD33 and subsequently CD123+ fractions of the GMP, where
IRF8 is highly expressed. In contrast, DC3 potential segregates
predominantly withmonocyte development through a different re-
gionof IRF8loGMPparameter spacemarkedbyCD33expression.
Two Trajectories of DC Development Connect the
Progenitor Compartment with Mature DCs
The forward trajectories of DC potential were mapped within the
CD34neg-int fraction of human BM. A gating strategy for these in-
termediate precursors was developed by iterative sorting and
in vitro culture experiments (Figure 4A). After lineage+ (lin),
CD34+, and mature DCs were removed, a population of
AXL+CD5+ cells was identified, corresponding to pre-DC and
‘‘AS’’ DC populations previously described (See et al., 2017; Vil-
lani et al., 2017). AXL+ cells expressed CD123, and variable
CD11c inversely correlated with IRF8 expression (Figure S4A).
Under our experimental conditions, CD1c AXL+CD5+ cells con-
tained only DC2 potential and were provisionally designated
‘‘early pre-DC2’’ (CD123hiCD11c) and ‘‘pre-DC2’’ (CD123int
CD11c+) (Figures 4B, S4B, and S4C). AXLCD5 cells were
then gated on a bivariate plot of CD123 and SIRPA/B (Figure 4A).
CD123+ cells (gate 1, teal) contained CD2+ andCD2 fractions of
CD303hiCD304hi (CD303/4) pDCs, as previously reported (Mat-
sui et al., 2009; Bryant et al., 2016). CD2+ cells had precursor
characteristics, with higher CD34 expression, more proliferative
potential, and phenotypic conversion to CD2 pDCs in vitro (Fig-
ures S4D–S4F). Tri-lineage potential was observed in the
CD123hiCD303/4lo gate (occupied by AXL+CD5+ cells, if not pre-
viously excluded) (Figure S4G).
The CD123neg-int SIRPA/B population (gate 2, dark purple)
contained CD34intCD123int cells enriched for cDC1 potential and
adjacent to cells with low expression of the cDC1 marker
CD141 (Figures 4A, 4B, and S4B). These CD34intCD123intSIRPA
‘‘early pre-cDC1s’’ corresponded to CD34loCD100+ cells with
cDC1 potential detected previously (See et al., 2017; Villani
et al., 2017), as confirmed by phenotypic and scRNA-seq analysis
of PB,where these cells formedadistinct clustermarkedbyNFIL3
(Figures 4C and S4L–S4R).
SIRPA/B+ cells (Figure 4A, gate 3, dark brown) contained
nearly all of the in vitro DC3 and monocyte potential. Among
CD34 SIRPA/B+ cells, CD2 expression enriched for DC3 poten-
tial (SIRPA+2+ ‘‘pre-DC3’’). Under these experimental condi-
tions, monocyte potential was relatively enriched in the CD2
‘‘pre-monocyte’’ fraction (Figures 4B, S4B, and S4C).
This analysis demonstrated highly enriched single lineage DC
potential within the CD34int parameter space linking CD34+
progenitors and CD34 mature DCs. This may be illustrated by
applying the gating described in Figure 4A to CD34 high,
Figure 4. Two Trajectories of DC Development Connect the Progenitor Compartment with Mature DCs
(A) Flow gating strategy used to identify DCs and their precursors in BM, including CD141+ cDC1s; CD1c+ DCs; AXL+CD5+ cells composed of CD123hiCD11c
(light pink) and CD123intCD11c+ (dark pink) fractions; CD2+ (light blue) and CD2 (dark blue) pDCs; CD123+CD303/4lo cells (turquoise); SIRPA/
BCD123intCD141 (lightest purple) and CD141lo (light purple) populations; and CD123SIRPA/B CD34int (brown), CD34CD2+ (dark orange), and CD34CD2
(gray) precursors.
(B) The output of in vitro culture of CD34int DC precursors FACS-purified from BM using the gating strategy described in (A). Population-specific output is ex-
pressed as a proportion (%) of the total cells captured by all DC and monocyte gates. CD123hi303/4lo (six experiments from four donors; 6;4); CD2+ pre-pDCs
(5;3); CD123hi5+ (4;3); CD123int5+ (4;3); CD34intCD123int (4;4); CD34intSIRPA+ (5;5); SIRPA+2+ (4;4); SIRPA+2 (4;4). Bars represent mean + SEM, and circles
represent individual experiments. Significant differences in the proportional output of DC2s versus DC3s (red) or DC3s versusmonocyte (black) are indicated: *p <
0.05; **p < 0.01 (paired, two-tailed t test).
(C) Flow gating strategy from (A) applied to linHLA-DR+ cells from HC BM fractionated by high, intermediate, and low CD34 expression, next to blood (columns)
for comparison of antigen expression levels among progenitor, precursor, and mature populations. Individual DC lineages are ordered in rows.
(D) Proliferative potential of FACS-purified DC and DC precursors estimated by CFSE dilution (see STAR Methods). CD34+progenitors and CD14+
monocytes were included as positive and negative controls, respectively. The CFSE dilution histograms for each precursor are grouped and ordered according to
their proposed position in the developmental trajectory for each DC lineage. Plots shown are representative of n = 3 experiments (summarized in Figure S4H).
(E and F) tSNE visualization of the first 20 principal components (explaining 35% total variance) of the transcriptomes of 244 single cells adaptively sampled from
linHLA-DR+ CD34neg-int precursor and mature DC populations of BM. tSNE plots are annotated by the gate of origin from index-linked flow (E) or by 15 clusters
generated from hierarchical clustering of all protein-coding non-cell-cycle genes (F), independently of surface phenotype (Figure S4K).
(G) Heatmaps showing the expression of key surface antigens (SAs) (index-linked flow) or log2 gene expression of TFs and FLT3 (scRNA-seq) across the tSNE
plot in (E) and (F). Black circles represent regions of high or low IRF8 expression, marked Al or Bl, respectively. The differential expression patterns of these regions
correspond to the patterns of regions ‘‘A’’ (IRF8hiCD123intGMP) and ‘‘B’’ (IRF8loGMP33+) in Figures 3E–3G.
(H and I) Diffusion map generated with all protein-coding, non-cell-cycle genes to infer pseudo-temporal ordering of cells and reconstruct lineage branching. (H)
Cells are colored according to the hierarchical clusters generated in Figure S4K. (I) IRF8 expression (log2). Diff C, diffusion component.
(J) Violin plot of differential IRF8 expression (log2) in clusters 10 (SIRPA+34int) and 12 (early pre-DC2). **p < 0.001 by Mann-Whitney U.
(K and L) MFI of intracellular IRF8 by flow analysis across gates identifying BM 34intSIRPA+ pre-DC3s and pre-mono and CD123hiCD5+ early pre-DC2s (K) and
CD5+ DC2s and CD5 DC3s (L) (n = 4). *p = 0.028 by Mann-Whitney U.
See also Figure S4.
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intermediate, and low fractions of linHLA-DR+ BM and PB cells
(Figure 4C). Carboxyfluorescein succinimidyl ester (CFSE) dilu-
tion assays showed a loss of proliferative potential in keeping
with the proposed maturation trajectories (Figures 4D and S4H).
Seeking independent support for the proposed pathways, we
performed scRNA-seq of CD34int precursors and mature DCs
from BM. Analysis used a computational pipeline driven only
by gene expression data, independently indexed to the cell-sur-
face phenotype used to define in vitro potential in the preceding
experiments (Figures 4E–4J and S4I–S4K). 244 of 260 cells with
expression of 12,137 protein-coding, non-cell-cycle genes
passed QC (STAR Methods; Table S3).
Unsupervised hierarchical clustering generated clusters, an-
notated by their expression of known DC-subset-specific genes,
that overlapped closely with indexed phenotypes (with the
exception of CD123intSIRPA cells, which were too rare to be
identified discretely; Figures 4E, 4F, and S4I–S4K).
In tSNE visualization, DC2s and DC3s lay in adjacent halves of
the CD1c+ DC population. DC2s (cluster 6), in the top half, were
connectedwithcDC1s (cluster 11),AXL+cells (cluster 12, express-
ingSIGLEC6), and pre-pDCs (clusters 3–5, expressing pDCgenes
JCHAIN andMZB1). DC3 (cluster 7,CD14 andVCAN), in the lower
half, were adjacent to CD34int SIRPA+ cells (cluster 15, VCAN) and
pre-monocytes (clusters 8 and 14,MPO and AZU1).
Two regions of the tSNE plot retained intermediate CD34
expression, marking immature precursor populations (Al and
Bl,; Figure 4G). Their phenotypes, TF expression, and in vitro po-
tentials corresponded very closely to the IRF8hi and IRF8lo re-
gions identified in the progenitor analysis (A and B, respectively;
Figure 3G). Specifically, A and Al shared high IRF8, CD123,
TCF4, and SPIB expression and gave rise to pDCs, cDC1s,
and DC2 in vitro, while B and Bl expressed low amounts of
IRF8 but high CD33 and SPI1(PU.1) and generated predomi-
nantly DC3s and monocytes in culture. FLT3 was expressed in
all DC precursors, including SIRPA+2+ pre-DC3, but not
SIRPA+2, pre-monocytes (Figure 4G).
Diffusion mapping defined distinct trajectories for cDC1s
(cluster 11), pDCs (clusters 1–5), DC2s and DC3s (clusters 6
and 7), and monocytes (clusters 8 and 9; Figure 4H; Data S2).
The DC2 trajectory originated in the CD123+CD11cCD5+ early
pre-DC2 population (clusters 12 and 13), adjacent to pDC origin,
distinct from the origin of DC3 in CD34intSIRPA+ pre-DC3 (clus-
ters 10, 14, and 15), close to monocyte origin. IRF8 transcription
and protein expression were higher in the DC2 trajectory than in
DC3 (Figures 4J and 4K). As expected, IRF8 protein was low in
both mature DC2s and DC3s (Figure 4L).
PBCD123int precursors were similar to those isolated fromBM
with respect to scRNA-seq profiles and in vitro culture potential.
IRF8hiCD123+CD2+AXL+CD5+ precursors, previously described
as pre-DC (See) and AS DC (Villani), generated only DC2s (Fig-
ures S4L–S4R).
Differential IRF8 Expression Defines the Two Pathways
of DC Development
Having identified the trajectories and key antigens mapping DC
differentiation in BM and PB, we sought to integrate progenitors,
precursors, and mature cells using an independent method. We
used a CyTOF panel including progenitor markers (CD34 and
CD117), intracellular TFs (IRF4 and IRF8), early DC lineage
markers (AXL, SIGLEC6, CD123, CD2, CD33, and SIRPA), and
mature DC and monocyte antigens (Figures 5A–5F and S5A–
S5E; Table S2) to simultaneously analyze cells from BM and
PB. Using tSNE dimension reduction, PB cells containing
pDCs, cDC1s, CD1c+ DCs, and classical and nonclassical
monocytes were located peripherally to progenitors and precur-
sors present in BM. Populations were identified by key antigen
expression or back-gating of sequentially gated populations
(Figures 5A, 5B, S5B, and S5C). As previously shown, CD1c+
DCs, including the DC3 portion, were distinct from classical
monocytes.
Superimposition of IRF8hi (red) and IRF8lo (orange) thresholds,
from a bivariate plot of IRF8 and CD304, revealed distinct
nonoverlapping regions of the tSNE plot (Figure 5C). IRF8hi re-
gions contained progenitors and precursors associated with
pDC, cDC1, and DC2 lineages in the preceding analyses and
AXL+SIGLEC6+ (IRF8hi CD123+) pre-DCs, present in PB and
BM, connected pDCs and cDC1s with the CD5+ BTLA+ pole of
CD1c+ DCs (Figures 5B–5D and S5B–S5D).
In contrast, progenitors and precursors with monocyte or DC3
potential (mapped by CD117, CD33, SIRPA, and CD11c) segre-
gated with low IRF8 expression and joined the CD1c+ DC cluster
at a point discrete from AXL+SIGLEC6+ cells (Figures 5E, S5B,
and S5C). CD34int expression was observed at both IRF8hi and
IRF8lo contact points with the CD1c+ DC population (Figure 5B).
As previously demonstrated (Figures 2C and 4L), IRF8 was not
expressed in mature CD1c+ DCs.
Figure 5. Differential IRF8 Expression Defines the Two Trajectories of DC Development
(A–E) CyTOF analysis of FACS-purified CD45+lin(CD3,19,20,56,161) PB and BM progenitors, precursors, and mature DCs and monocytes using a panel of 33
surface antigens and two intracellular stains (IRF4 and IRF8). (A) tSNE visualization of linHLA-DR+ cells, down-sampled to select 75,000 cells (20,000
CD11b+CD14+ monocytes, 4,000 CD11b+CD16+ monocytes, and 50,000 non-monocyte cells). PB (red) and BM (gray) cells were distinguished by differential
CD45+ conjugate staining and displayed across tSNE space. (B) Heatmap of DC or monocyte-subset-specific antigens displayed on tSNE plots as in (A) (blue-
yellow-red scales represent channel values). ‘‘Mature cells’’ plot shows the location of DC and monocyte subsets and CD34+ progenitors, identified by back-
gating from bivariate plots (Figures S5B–S5D). (C) The location in tSNE space of IRF8hi (red) and IRF8lo (orange) expressing cells identified by (1) standard gating
on a bivariate plot of IRF8 versus CD304 and superimposition of these gated cells on tSNE space and (2) a heatmap of IRF8 expression across all cells. (D and E)
Location in tSNE space of progenitors and precursors with pDC, cDC1, or DC2 (D) and DC3 or monocyte (E) potential as defined by previous experiments,
identified by back-gating from bivariate plots (Figures S5B and S5C), and heatmaps of associated antigens.
(F) Diffusion map generated with 14,000 cells including GMPs, precursor and mature DCs, and monocytes. Populations were identified and color-coded ac-
cording to Figures 3A (progenitors) and 4A (precursors, DCs, and monocytes), applied to CyTOF data as shown in Figures S5B and S5C. Heatmaps show the
expression (log2) of IRF8 and key antigens superimposed across the diffusion map trajectories. See also Figure S5E. Diff C, diffusion component.
(G) Histograms summarizing IRF8 protein expression by flow cytometry (MFI) in progenitors, precursors, and mature cells of pDC, cDC1, DC2, and DC3 lineages
from BM and PB. Bars show mean ± SEM. Circles show individual donors (BM progenitors, n = 4; BM and PB precursors and mature DCs, n = 3).
See also Figure S5.
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Diffusion mapping of 14,000 randomly sampled GMP, precur-
sor, and mature populations from the experiment produced a
result coherent with the preceding in vitro culture outputs and
with trajectories driven by scRNA-seq data (Figure 5F; Data
S3). The analysis generated a tetrahedron in Euclidean space
with progenitors at the apex and monocytes, pDCs, and
cDC1s at the vertices. DC3 and DC3 precursors lay close to
the monocyte pathway linked to the GMP33+ by IRF8lo popula-
tions (brown and rust). DC2 precursors descended closer to
pDCs through CD123lo-int IRF8hi GMPs (lilac). As expected,
mature DC2s and DC3s lay between monocytes and DCs along
diffusion component 1. Both mature populations expressed
FCER1, SIRPA, and CD2, but there was mutually exclusive
expression of CD14 and CD5. These pathways could be visual-
ized on standard bivariate plots (Figures S5F and S5G). Intracel-
lular flow was used to pinpoint the stage-specific expression
of IRF8 protein along each pathway of DC development
(Figure 5G).
IRF8hi and IRF8lo Pathways Are Differentially
Compromised in IRF8 Deficiency
We analyzed nine individuals from three kindreds with IRF8
mutation to define the dependence of each pathway of DC
development on IRF8 activity. Bi-allelic IRF8K108E/K108E and
IRF8R83C/R291Q patients were compared with their minimally
affected heterozygous parents (Hambleton et al., 2011; Bigley
et al., 2018) and three individuals from a third kindred with an
autosomal-dominant phenotype due to dominant-negative
IRF8V426fs (unpublished data).
Heterozygous parents of the child carrying IRF8R83C/R291Q had
20%–50% loss of pDCs, cDC1s, and CD1c+ DCs (Figures 6A
and 6B). In retrospect this matched the phenotype of heterozy-
gous IRF8K108E (Hambleton et al., 2011) and is in keeping with
a gene-dosage effect of IRF8 on DC development. IRF8V426fs
mutation produced an intermediate cellular phenotype
congruent with clinical manifestations that were more severe
than heterozygotes (IRF8R83C and IRF8R291Q) but less than bi-
allelic IRF8 deficiency (IRF8R83C/R291Q) (Figures 6A, 6B, and
S6A). Both pDCs and cDC1s were depleted with V426fs muta-
tion. A trend toward monocytosis in the asymptomatic heterozy-
gotes (IRF8R83C and IRF8R291Q) became significant in IRF8V426fs.
CD1c+ DCs presented a paradox; although IRF8R83C and
IRF8R291Q were lower than controls, lower IRF8 activity in
IRF8V426fs restored CD1c+ DCs (Figure 6C). The proportion of
DC2s and DC3s accounted for this anomaly; DC2s, pDCs, and
cDC1s decreased with loss of IRF8, but this was compensated
for by an increase in DC3 such that CD1c+ DC population of
IRF8V426fs consisted almost entirely of DC3s (Figure 6D). Parallel
effects occurred in pre-DCs as defined by the preceding anal-
ysis; AXL+CD5+ pre-DC2s were lost in parallel with DC2s, but
SIRPA/B+CD2+ pre-DC3s increased proportionately with DC3s
and monocytes (Figures 6E and 6F). In heterozygotes with suffi-
cient cells to analyze, loss of IRF8 reduced tumor necrosis factor
(TNF) and IL-12 in DC2s and DC3s while IFN-a and TNF produc-
tion was decreased in CD2+pre-pDCs and pDCs (Figures 6G,
6H, S6B, and S6C).
IRF8 Deficiency Causes Dose-Dependent Blockade of
the IRF8hi Pathway
Seeking further evidence of a dissociation between IRF8hi and
IRF8lo DC pathways, we probed the progenitor and DC precur-
sor compartments of BM for dose-dependent effects of
IRF8V426fs and IRF8R83C/R291Q (Figures 7A, 7B, and S7A). We in-
ferred the point of developmental blockade by expansion of a
proximal population coupled with loss of cells immediately distal
to it (red arrows, Figure 7C). In the IRF8hi pathway, defects
occurred increasingly more proximally; heterozygous mutations
affected the precursors, and dominant-negative and bi-allelic
mutations impacted the proportions of CD123lo, CD123int, and
CD33CD117 GMPs in a stepwise fashion. In contrast, the
IRF8lo pathway leading to DC3s was only sensitive to complete
bi-allelic loss of IRF8, late in the precursor compartment.
In vitro differentiation and transcriptomic analyses provided
evidence of two pathways of DC development, distinguished
by their high or low IRF8 expression, giving rise to cDC1s,
pDCs, and DC2s or DC3s and monocytes, respectively.
In partial IRF8 deficiency, the incremental loss of subsets
derived from the IRF8hi trajectory, associated with preserva-
tion or expansion of IRF8lo populations, demonstrates the
differential IRF8 requirement of these pathways in the
intact human.
DISCUSSION
CD1c+ DCs are heterogeneous by phenotype, gene expression,
and function. DC2s are enriched for classical cDC1-related
Figure 6. IRF8hi and IRF8lo Pathways Are Differentially Compromised in IRF8 Deficiency
(A) PB flow analysis of monocytes and DCs in subjects carrying heterozygous IRF8R83C or IRF8R291Qmutation (Het), their child carrying IRF8R83C/R291Q (Bi), and a
carrier of dominant-negative heterozygous mutation IRF8V426fs (Dom) compared with HC (Cont).
(B) Trucount quantification of PB DCs and monocytes in subjects carrying IRF8 mutations (gating shown in Figure S6A; Hambleton et al., 2011; Bigley et al.,
2018)). Cont, n = 25; Het, n = 4 (IRF8R83C, IRF8R291Q, and two subjects carrying IRF8K108E); Dom, n = 3 (IRF8V426fs); Bi, n = 2 (IRF8R83C/R291Q and IRF8K108E/K108E).
(C) Flow cytometry phenotyping of CD1c+ DC subsets derived from the CD1c+CD2+ gate (gray) in (A) to identify CD14+ DC3s (orange), CD14BTLA DC3s (light
orange), CD5BTLA+ DC2s (light red), and CD5+BTLA+ DC2s (red).
(D) Proportion of CD1c+ DC subsets (gated as in C, from the individuals represented in B). C, control; H, heterozygous parents; D, dominant-negative hetero-
zygotes (IRF8V426fs).
(E) Flow analysis of DC and monocyte precursors in PB of subjects carrying IRF8 mutations as shown, gated as in Figure 4C.
(F) Proportion of DC and monocyte precursors out of all pre-DCs in PB of subjects carrying IRF8 mutations, gated as in (E). C, control; H, heterozygous; D,
IRF8V426fs
(G and H) Intracellular flow analysis of in vitro cytokine elaboration (percentage of positive cells) by CD14+ monocytes (black), CD14+ DC3s (orange),
CD14CD5CD1c+ DCs (gray), and CD5+ DC2s (red) (G) and CD2+ pre-pDCs and pDCs from HC (n = 8) and subjects carrying heterozygous IRF8R83C, IRF8R291Q
(mean of technical duplicates) or IRF8V426fs (IRF8, red-outlined bars) (H). See also STAR Methods and Figure 1H.
Bars show mean ± SEM, and circles represent individual subjects. *p < 0.05; **p < 0.01; ***p < 0.001; ^p = 0.053, Mann-Whitney U. See also Figure S6.
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properties, while DC3s are closer to monocytes (Schrøder et al.,
2016; Yin et al., 2017; Alca´ntara-Herna´ndez et al., 2017; Kore-
nfeld et al., 2017; Villani et al., 2017; Bourdely et al., 2020).
Here, we have shown that this heterogeneity originated in two
distinct pathways of hematopoiesis, with differential require-
ments for IRF8. Using in vitro differentiation assays tuned to
distinguish between DC2 and DC3 outputs, we showed that their
developmental potentials lie in mutually exclusive populations of
progenitors and precursors. Two developmental trajectories
were apparent from high-dimensional analysis of antigen
expression, unbiased scRNA-seq, and diffusion mapping.
Finally, a human IRF8 allelic series revealed differential sensitivity
of the two pathways to loss of IRF8 activity.
The DC2 IRF8hi pathway followed a classical DC trajectory
closely related to pDCs and cDC1s. Distinct DC2 potential was
first evident in LMPPs, which were heterogeneous at single-
cell resolution, and was traceable through CD123loCD33
CD117 GMPs. Progressive enrichment of IRF8hi pathway DC
potential was observed with increasing CD123 expression in
the GMP compartment. The maximum expression of CD123 by
GMPs was CD123int relative to CD123hi expression in PB. The
CD123+ tip of the GMP generated the CD123hi cells found
among CD34int BM and PB cells, containing restricted pDC
and DC2 potential. CD5 and transient expression of AXL and
SIGLEC6 separated these two components. As CD123 expres-
sion was lost, the characteristic CD1c+ DC markers CD11c
and CD1c were progressively acquired, IRF8 was downregu-
lated, and IRF4 dominance was acquired. pDCs developed
along a CD123hi trajectory marked by continued high expression
of IRF8 and IRF4, acquiring CD303/4 as CD34 expression was
lost. The cDC1 trajectory, characterized by the highest IRF8
expression, took a variant route from the GMP. The most en-
riched flux appeared to leave the CD123int tip of the GMP as a
small population of cells retaining residual proliferative capacity
and CD34int expression. These became CD123intCD11clo PB
cells that subsequently acquired CD141, CLEC9A, and a state
of high IRF8 unopposed by IRF4. This population was previously
detected among multiply lineage-negative cells by co-expres-
sion of CD100 and CD34 but not connected to the cDC1 trajec-
tory (Villani et al., 2017). Pre-DC2s and pre-cDC1s were much
more obvious when linHLA-DR+ BM cells were fractionated
by decrements of CD34 expression.
The DC3 pathway was related to monocyte development,
marked by low expression of IRF8. However, DC3s are not
‘‘monocyte derived’’ for the following reasons: (1) they were
observed fully formed in the BM compartment, (2) their potential
was highest in a phenotypically defined precursor group inde-
pendent of monocytes (SIRPA/B+CD2+), (3) they appeared in
progenitor cell culture earlier thanmonocytes, and (4) they devel-
oped under conditions that prevent monocyte differentiation
into DC3.
Enrichment for DC2 and DC3 potential within discrete progen-
itor populations is congruent with lineage-primed descriptions of
hematopoiesis, in which DC potential is specified at an early
stage (Schlitzer et al., 2015; Lee et al., 2017). Specifically, we
observed DC2 trajectory transcriptomes in subsets of LMPP
and CD123neg-loCD33 GMP and DC3 and monocyte-related
transcriptomes, distinct from granulocyte precursors, in the
CD123neg-loCD33+ GMP.
The developmental trajectories of pDCs, cDC1s, and CD1c+
DCs (DC2 and DC3 together) have been previously mapped at
single-cell resolution by Lee et al. (2017), who demonstrated
that the CD123int GMP contains only unipotent cell potential
(pDCs, cDC1s, or CD1c+ DCs) and that the CD123neg-lo GMP
contains cells with dual cDC1 and CD1c+ DC or CD1c+ DC
and mono- potential. Herein, we have shown that the cDC1
and CD1c+DC potential of CD123lo-intGMP gave rise almost
exclusively to DC2 while the greatest enrichment of monocyte
and DC3 potential was found in the CD123neg-loCD33+ subset
of GMP. The use of single cultures would not alter the interpreta-
tion of our data that the outputs of these two GMP fractions are
distinct. Where single-cell cultures will be essential, in future ex-
periments, is to explore lineage-priming at the origin of the DC2
and DC3 pathways in primitive HSC or MPP populations. It also
remains to be determined whether alternative exogenous factors
can modulate the potentials demonstrated in vitro.
Many reports have highlighted dose-dependent effects of Irf8
on murine DC development (Tailor et al., 2008; Grajales-Reyes
et al., 2015; Sichien et al., 2016). Collectively, these show that
cDC1s are most sensitive to Irf8 loss, requiring high expression
at the terminal stages of differentiation. Murine pDCs survive
Irf8 deficiency but are functionally altered, while the equivalents
of CD1c+ DCs (cDC2s) are preserved. Monocytes are not
affected until Irf8 is ablated, when they are blocked at the
GMP stage.
In humans, reduced IRF8 activity in asymptomatic heterozy-
gotes and individuals with the dominant-negative V426fs allele
was associated with reduction or depletion of all of the IRF8hi
pathway classical DCs (pDCs, cDC1s, and DC2s). In contrast,
IRF8lo DC3s and monocytes were maintained or even expanded
until IRF8 activity was completely absent in the patients carrying
bi-allelic mutations, resulting in the loss of all DCs and mono-
cytes. In contrast to mouse, human pDCs were almost as sensi-
tive as cDC1s to loss of IRF8. However, in asymptomatic hetero-
zygotes, where there was only partial depletion, we observed an
increased proportion of CD2+ pDCs and functional deficits in
IFN-a and TNF production similar to that reported in mice (Si-
chien et al., 2016). When CD1c+DCs are considered as a single
Figure 7. IRF8 Deficiency Causes Dose-Dependent Blockade of the IRF8hi Pathway
(A and B) Flow cytometry analysis of BMCD34+ progenitors (A) and DC andmonocyte precursors (B) from the subjects carrying dominant-negative IRF8V426fs and
bi-allelic IRF8 mutations and an age-matched control (AM Cont). BM was not available from healthy heterozygotes IRF8R83C and IRF8R291Q. Gating and color
coding as in Figures 3A and 4C.
(C) The relative proportions of progenitors and precursors in BM and PB from controls (n = 3 BM, n = 4 PB) and individuals carrying heterozygous IRF8R83C and
IRF8R291Q (PB, Het), IRF8V426fs (Dom), or IRF8R83C/R291Q (Bi) to pinpoint the block associated with progressive loss of IRF8 activity for each DC lineage. CD34+
populations were expressed as a proportion of total gated CD34+ cells. Precursor andmature DC populations were expressed as a proportion of the total number
of gated CD34neg-int cells. Likely points of blockade are indicated by red arrows.
See also Figure S7.
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entity, the total population appeared to remain intact in the
context of partial depletion of IRF8, as observed in asymptom-
atic heterozygotes and individuals with the dominant-negative
V426fs allele. However, separation of CD1c+ DCs into IRF8hi
pathway DC2 and IRF8lo pathway DC3 components showed
that DC3s populated the parameter space left empty by missing
DC2s. A dominant-negative allele of IRF8 has been previously re-
ported with the substitution T80A (Hambleton et al., 2011).
Although this was originally thought to have intact cDC1s and
a defect of CD1c+ DCs, improved analysis using CLEC9A
recently confirmed that cDC1s are indeed selectively depleted
in these heterozygous individuals (Kong et al., 2018). Lower
expression of CD1c is also possibly explained by replacement
of DC2 by DC3. Thus, all IRF8-mutated individuals now show
congruous cellular phenotypes.
These observations highlight the phenomenon that cellular
deficiency due to hematopoietic TF mutation often results in
expansion of related lineages, owing to the unopposed action
of competing TFs. We have previously described the marked
neutrophilia accompanying bi-allelic IRF8 deficiency (Hambleton
et al., 2011; Bigley et al., 2018), probably due to the action of un-
opposed CEBPa (Becker et al., 2012; Kurotaki et al., 2014). In
this study, we have reported monocytosis and expansion of
DC3 in IRF8 heterozygous states potentially related to excessive
SPI1 (PU.1) activity when IRF8 is partially absent (Lee et al., 2017;
Giladi et al., 2018).
Our results reinforce the view that gene-dosage effects and
autosomal-dominant patterns of inheritance often occur in
TFs controlled by super-enhancers (Afzali et al., 2017). Experi-
mentally, this proved critical in analyzing the differential
requirement for IRF8 between two DC pathways. Through this
analysis, we have refined the concept of ‘‘classical DCs’’ as
cDC1 and DC2 dependent on the IRF8hi pathway and distinct
from DC3 and monocyte development by the IRF8lo pathway.
Although we do not have a biochemical means of assessing to-
tal IRF8 ‘‘activity’’ in the intact hematopoietic system and made
inferences from the severity of clinical phenotypes, all the mu-
tations described are deleterious in reporter assays (Bigley
et al., 2018).
In conclusion, our data support a model whereby CD1c+ DC
heterogeneity arises from distinct lineage trajectories within the
CD34+ progenitor compartment, progressing along pathways
distinguished by high or low IRF8 expression, comprised of
phenotypically identifiable precursors. Distal convergence to a
CD1c+ DC phenotype results in the observed phenotypic, tran-
scriptomic, and functional heterogeneity of CD1c+ DCs.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITY
B Lead Contact
B Materials Availability
B Data and Code Availability
B Subject Details
B Patients and healthy donors
d METHOD DETAILS
B Flow cytometry and cell sorting
B In vitro generation of dendritic cells
B Dendritic cell functional analysis
B NanoString nCounter analysis
B Single cell RNA sequencing
B Alignment of reads to the human reference genome
B Gene and cell filtering
B Cell clustering
B tSNE analysis
B Diffusion maps and lineage tracing
B Helios Mass Cytometer (CyTOF) analysis
B tSNE analysis
B Diffusion maps and lineage tracing
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental Information can be found online at https://doi.org/10.1016/j.
immuni.2020.07.003.
ACKNOWLEDGMENTS
We gratefully thank healthy donors, patients and their families for their partic-
ipation. We thank NIHR BioResource volunteers for their participation, and we
gratefully acknowledge the NIHR Bioresource Centre, NHS Trusts, and staff
for their contribution. We thank the National Institute for Health Research,
NHS Blood and Transplant, and Health Data Research UK as part of the Digital
Innovation Hub Programme. The views expressed are those of the author(s)
and not necessarily those of the NHS, the NIHR or the Department of Health
and Social Care. We also thank staff at the Newcastle University Flow Cytom-
etry Core Facility (FCCF) for assistance with the generation of flow cytometry
data, as well as Lorna Witty and James Docker from the Oxford Genomics
Centre (Wellcome Centre for Human Genetics, Oxford, UK). This work was
supported by grants from the Wellcome Trust (101155/Z/13/Z to V.B. and
U.C.), CRUK (C30484/A21025 to M.C.), Newcastle University Single Cell
Unit, and the NIHR Newcastle Biomedical Research Centre at Newcastle
upon Tyne Hospitals.
AUTHOR CONTRIBUTIONS
Conceptualization, M.C. and V.B.; Methodology, U.C., A.R., S.P., K.G., P.M.,
S.M., D.D., G.H., A.F., B.C., R.Q., M.C., and V.B.; Software, A.R. and R.Q.;
Formal Analysis, U.C., A.R., K.G., R.Q., and V.B.; Investigation, U.C., A.R.,
S.P., K.G., P.M., S.M., D.D., G.H., B.C., R.Q., G.D., and V.B.; Resources, S.H.,
R.H., H.L.A., J.E.D.T., G.D., M.C., and V.B.; Data Curation, U.C., A.R., S.P.,
D.D., and V.B.; Writing – Original Draft, U.C., A.R., M.C., and V.B.; Writing – Re-
view & Editing, D.M., G.H., A.F., S.H., and G.D.; Visualization, U.C., A.R., M.C.,
and V.B.; Supervision, M.C. and V.B.; Funding Acquisition, M.C. and V.B.
DECLARATION OF INTERESTS
The authors declare no competing interests.
Received: March 26, 2019
Revised: December 27, 2019
Accepted: July 2, 2020
Published: July 30, 2020
REFERENCES
Afzali, B., Gro¨nholm, J., Vandrovcova, J., O’Brien, C., Sun, H.W.,
Vanderleyden, I., Davis, F.P., Khoder, A., Zhang, Y., Hegazy, A.N., et al.
(2017). BACH2 immunodeficiency illustrates an association between super-
enhancers and haploinsufficiency. Nat. Immunol. 18, 813–823.
ll
OPEN ACCESS Article
16 Immunity 53, 1–18, August 18, 2020
Please cite this article in press as: Cytlak et al., Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development
in Humans, Immunity (2020), https://doi.org/10.1016/j.immuni.2020.07.003
Alca´ntara-Herna´ndez, M., Leylek, R., Wagar, L.E., Engleman, E.G., Keler, T.,
Marinkovich, M.P., Davis, M.M., Nolan, G.P., and Idoyaga, J. (2017). High-
dimensional phenotypic mapping of human dendritic cells reveals interindi-
vidual variation and tissue specialization. Immunity 47, 1037–1050.e6.
Anders, S., Pyl, P.T., and Huber, W. (2015). HTSeq—a Python framework to
work with high-throughput sequencing data. Bioinformatics 31, 166–169.
Angerer, P., Haghverdi, L., B€uttner, M., Theis, F.J., Marr, C., and Buettner, F.
(2016). destiny: diffusion maps for large-scale single-cell data in R.
Bioinformatics 32, 1241–1243.
Becker, A.M., Michael, D.G., Satpathy, A.T., Sciammas, R., Singh, H., and
Bhattacharya, D. (2012). IRF-8 extinguishes neutrophil production and pro-
motes dendritic cell lineage commitment in both myeloid and lymphoid mouse
progenitors. Blood 119, 2003–2012.
Bigley, V., Maisuria, S., Cytlak, U., Jardine, L., Care, M.A., Green, K.,
Gunawan, M., Milne, P., Dickinson, R., Wiscombe, S., et al. (2018). Biallelic
interferon regulatory factor 8 mutation: A complex immunodeficiency syn-
drome with dendritic cell deficiency, monocytopenia, and immune dysregula-
tion. J. Allergy Clin. Immunol. 141, 2234–2248.
Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible
trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120.
Bourdely, P., Anselmi, G., Vaivode, K., Ramos, R.N., Missolo-Koussou, Y.,
Hidalgo, S., Tosselo, J., Nun˜ez, N., Richer, W., Vincent-Salomon, A., et al.
(2020). Transcriptional and Functional Analysis of CD1c+Human Dendritic
Cells Identifies a CD163+Subset Priming CD8+CD103+T Cells. Immunity 53,
https://doi.org/10.1016/j.immuni.2020.06.002.
Bryant, C., Fromm, P.D., Kupresanin, F., Clark, G., Lee, K., Clarke, C., Silveira,
P.A., Suen, H., Brown, R., Newman, E., et al. (2016). A CD2 high-expressing
stress-resistant human plasmacytoid dendritic-cell subset. Immunol. Cell
Biol. 94, 447–457.
Cisse, B., Caton, M.L., Lehner, M., Maeda, T., Scheu, S., Locksley, R.,
Holmberg, D., Zweier, C., den Hollander, N.S., Kant, S.G., et al. (2008).
Transcription factor E2-2 is an essential and specific regulator of plasmacytoid
dendritic cell development. Cell 135, 37–48.
Collin, M., and Bigley, V. (2018). Human dendritic cell subsets: an update.
Immunology 154, 3–20.
Cytlak, U., Resteu, A., Bogaert, D., Kuehn, H.S., Altmann, T., Gennery, A.,
Jackson, G., Kumanovics, A., Voelkerding, K.V., Prader, S., et al. (2018).
Ikaros family zinc finger 1 regulates dendritic cell development and function
in humans. Nat. Commun. 9, 1239.
Dickinson, R.E., Milne, P., Jardine, L., Zandi, S., Swierczek, S.I., McGovern,
N., Cookson, S., Ferozepurwalla, Z., Langridge, A., Pagan, S., et al. (2014).
The evolution of cellular deficiency in GATA2 mutation. Blood 123, 863–874.
Dobin, A., and Gingeras, T.R. (2015). Mapping RNA-seq reads with STAR.
Curr. Protoc. Bioinformatics 51, 11.14.1–11.14.19.
Durinck, S., Moreau, Y., Kasprzyk, A., Davis, S., De Moor, B., Brazma, A., and
Huber, W. (2005). BioMart and Bioconductor: a powerful link between biolog-
ical databases and microarray data analysis. Bioinformatics 21, 3439–3440.
Giladi, A., Paul, F., Herzog, Y., Lubling, Y., Weiner, A., Yofe, I., Jaitin, D.,
Cabezas-Wallscheid, N., Dress, R., Ginhoux, F., et al. (2018). Single-cell char-
acterization of haematopoietic progenitors and their trajectories in homeosta-
sis and perturbed haematopoiesis. Nat. Cell Biol. 20, 836–846.
Grajales-Reyes, G.E., Iwata, A., Albring, J., Wu, X., Tussiwand, R., Kc, W.,
Kretzer, N.M., Brisen˜o, C.G., Durai, V., Bagadia, P., et al. (2015). Batf3 main-
tains autoactivation of Irf8 for commitment of a CD8a(+) conventional DC clo-
nogenic progenitor. Nat. Immunol. 16, 708–717.
Granot, T., Senda, T., Carpenter, D.J., Matsuoka, N., Weiner, J., Gordon, C.L.,
Miron, M., Kumar, B.V., Griesemer, A., Ho, S.-H., et al. (2017). Dendritic cells
display subset and tissue-specific maturation dynamics over human life.
Immunity 46, 504–515.
Guilliams, M., Dutertre, C.A., Scott, C.L., McGovern, N., Sichien, D., Chakarov,
S., Van Gassen, S., Chen, J., Poidinger, M., De Prijck, S., et al. (2016).
Unsupervised high-dimensional analysis aligns dendritic cells across tissues
and species. Immunity 45, 669–684.
Haghverdi, L., Buettner, F., and Theis, F.J. (2015). Diffusion maps for high-
dimensional single-cell analysis of differentiation data. Bioinformatics 31,
2989–2998.
Hambleton, S., Salem, S., Bustamante, J., Bigley, V., Boisson-Dupuis, S.,
Azevedo, J., Fortin, A., Haniffa, M., Ceron-Gutierrez, L., Bacon, C.M., et al.
(2011). IRF8 mutations and human dendritic-cell immunodeficiency. N. Engl.
J. Med. 365, 127–138.
Helft, J., Anjos-Afonso, F., van der Veen, A.G., Chakravarty, P., Bonnet, D., and
Reis e Sousa, C. (2017). Dendritic cell lineage potential in human early hemato-
poietic progenitors. Cell Rep. 20, 529–537.
Kirkling, M.E., Cytlak, U., Lau, C.M., Lewis, K.L., Resteu, A., Khodadadi-
Jamayran, A., Siebel, C.W., Salmon, H., Merad, M., Tsirigos, A., et al. (2018).
Notch signaling facilitates in vitro generation of cross-presenting classical
dendritic cells. Cell Rep. 23, 3658–3672.e6.
Kiselev, V.Y., Kirschner, K., Schaub, M.T., Andrews, T., Yiu, A., Chandra, T.,
Natarajan, K.N., Reik, W., Barahona, M., Green, A.R., and Hemberg, M.
(2017). SC3: consensus clustering of single-cell RNA-seq data. Nat.
Methods 14, 483–486.
Kong, X.F., Martinez-Barricarte, R., Kennedy, J., Mele, F., Lazarov, T.,
Deenick, E.K., Ma, C.S., Breton, G., Lucero, K.B., Langlais, D., et al. (2018).
Disruption of an antimycobacterial circuit between dendritic and helper
T cells in human SPPL2a deficiency. Nat. Immunol. 19, 973–985.
Korenfeld, D., Gorvel, L., Munk, A., Man, J., Schaffer, A., Tung, T., Mann, C.,
and Klechevsky, E. (2017). A type of human skin dendritic cell marked by
CD5 is associated with the development of inflammatory skin disease. JCI
Insight 2, 2.
Kurotaki, D., Yamamoto, M., Nishiyama, A., Uno, K., Ban, T., Ichino, M.,
Sasaki, H., Matsunaga, S., Yoshinari, M., Ryo, A., et al. (2014). IRF8 inhibits
C/EBPa activity to restrain mononuclear phagocyte progenitors from differen-
tiating into neutrophils. Nat. Commun. 5, 4978.
Laurenti, E., and Go¨ttgens, B. (2018). From haematopoietic stem cells to com-
plex differentiation landscapes. Nature 553, 418–426.
Lee, J., Breton, G., Oliveira, T.Y., Zhou, Y.J., Aljoufi, A., Puhr, S., Cameron,
M.J., Se´kaly, R.P., Nussenzweig, M.C., and Liu, K. (2015). Restricted dendritic
cell and monocyte progenitors in human cord blood and bone marrow. J. Exp.
Med. 212, 385–399.
Lee, J., Zhou, Y.J., Ma, W., Zhang, W., Aljoufi, A., Luh, T., Lucero, K., Liang, D.,
Thomsen, M., Bhagat, G., et al. (2017). Lineage specification of human den-
dritic cells is marked by IRF8 expression in hematopoietic stem cells andmulti-
potent progenitors. Nat. Immunol. 18, 877–888.
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G.,
Abecasis, G., and Durbin, R.; 1000 Genome Project Data Processing
Subgroup (2009). The sequence alignment/map format and SAMtools.
Bioinformatics 25, 2078–2079.
Macosko, E.Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M.,
Tirosh, I., Bialas, A.R., Kamitaki, N., Martersteck, E.M., et al. (2015). Highly par-
allel genome-wide expression profiling of individual cells using nanoliter drop-
lets. Cell 161, 1202–1214.
Matsui, T., Connolly, J.E., Michnevitz, M., Chaussabel, D., Yu, C.I., Glaser, C.,
Tindle, S., Pypaert, M., Freitas, H., Piqueras, B., et al. (2009). CD2 distin-
guishes two subsets of human plasmacytoid dendritic cells with distinct
phenotype and functions. J. Immunol. 182, 6815–6823.
McCarthy, D.J., Campbell, K.R., Lun, A.T., and Wills, Q.F. (2017). Scater: pre-
processing, quality control, normalization and visualization of single-cell RNA-
seq data in R. Bioinformatics 33, 1179–1186.
Murphy, T.L., Grajales-Reyes, G.E., Wu, X., Tussiwand, R., Brisen˜o, C.G.,
Iwata, A., Kretzer, N.M., Durai, V., and Murphy, K.M. (2016). Transcriptional
control of dendritic cell development. Annu. Rev. Immunol. 34, 93–119.
Naik, S.H., Perie´, L., Swart, E., Gerlach, C., van Rooij, N., de Boer, R.J., and
Schumacher, T.N. (2013). Diverse and heritable lineage imprinting of early hae-
matopoietic progenitors. Nature 496, 229–232.
Nakano, T., Kodama, H., and Honjo, T. (1994). Generation of lymphohemato-
poietic cells from embryonic stem cells in culture. Science 265, 1098–1101.
ll
OPEN ACCESSArticle
Immunity 53, 1–18, August 18, 2020 17
Please cite this article in press as: Cytlak et al., Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development
in Humans, Immunity (2020), https://doi.org/10.1016/j.immuni.2020.07.003
Notta, F., Zandi, S., Takayama, N., Dobson, S., Gan, O.I., Wilson, G.,
Kaufmann, K.B., McLeod, J., Laurenti, E., Dunant, C.F., et al. (2016). Distinct
routes of lineage development reshape the human blood hierarchy across
ontogeny. Science 351, aab2116.
Ouwehand, W.H. (2019). Whole-genome sequencing of rare disease patients
in a national healthcare system. bioRxiv. https://doi.org/10.1101/507244.
Paul, F., Arkin, Y., Giladi, A., Jaitin, D.A., Kenigsberg, E., Keren-Shaul, H.,
Winter, D., Lara-Astiaso, D., Gury, M., Weiner, A., et al. (2015).
Transcriptional heterogeneity and lineage commitment in myeloid progenitors.
Cell 163, 1663–1677.
Pellin, D., Loperfido, M., Baricordi, C., Wolock, S.L., Montepeloso, A.,
Weinberg, O.K., Biffi, A., Klein, A.M., and Biasco, L. (2019). A comprehensive
single cell transcriptional landscape of human hematopoietic progenitors. Nat.
Commun. 10, 2395.
Picelli, S., Faridani, O.R., Bjo¨rklund, A.K., Winberg, G., Sagasser, S., and
Sandberg, R. (2014). Full-length RNA-seq from single cells using Smart-
seq2. Nat. Protoc. 9, 171–181.
Risso, D., Ngai, J., Speed, T.P., and Dudoit, S. (2014). Normalization of RNA-
seq data using factor analysis of control genes or samples. Nat. Biotechnol.
32, 896–902.
Salem, S., Langlais, D., Lefebvre, F., Bourque, G., Bigley, V., Haniffa, M.,
Casanova, J.L., Burk, D., Berghuis, A., Butler, K.M., et al. (2014). Functional
characterization of the human dendritic cell immunodeficiency associated
with the IRF8(K108E) mutation. Blood 124, 1894–1904.
Satpathy, A.T., Brisen˜o, C.G., Cai, X., Michael, D.G., Chou, C., Hsiung, S.,
Bhattacharya, D., Speck, N.A., and Egawa, T. (2014). Runx1 and Cbfb regulate
the development of Flt3+ dendritic cell progenitors and restrict myeloprolifer-
ative disorder. Blood 123, 2968–2977.
Schlitzer, A., Sivakamasundari, V., Chen, J., Sumatoh, H.R., Schreuder, J.,
Lum, J., Malleret, B., Zhang, S., Larbi, A., Zolezzi, F., et al. (2015).
Identification of cDC1- and cDC2-committed DC progenitors reveals early
lineage priming at the common DC progenitor stage in the bone marrow.
Nat. Immunol. 16, 718–728.
Schrøder, M., Melum, G.R., Landsverk, O.J., Bujko, A., Yaqub, S., Gran, E.,
Aamodt, H., Bækkevold, E.S., Jahnsen, F.L., and Richter, L. (2016). CD1c-
expression by monocytes: implications for the use of commercial CD1c+ den-
dritic cell isolation kits. PLoS ONE 11, e0157387.
See, P., Dutertre, C.A., Chen, J., G€unther, P., McGovern, N., Irac, S.E.,
Gunawan, M., Beyer, M., H€andler, K., Duan, K., et al. (2017). Mapping the hu-
man DC lineage through the integration of high-dimensional techniques.
Science 356, eaag3009.
Sichien, D., Scott, C.L., Martens, L., Vanderkerken, M., Van Gassen, S.,
Plantinga, M., Joeris, T., De Prijck, S., Vanhoutte, L., Vanheerswynghels, M.,
et al. (2016). IRF8 transcription factor controls survival and function of termi-
nally differentiated conventional and plasmacytoid dendritic cells, respec-
tively. Immunity 45, 626–640.
Spinelli, L., Carpentier, S., Montan˜ana Sanchis, F., Dalod, M., and Vu Manh,
T.P. (2015). BubbleGUM: automatic extraction of phenotype molecular signa-
tures and comprehensive visualization of multiple gene set enrichment ana-
lyses. BMC Genomics 16, 814.
Street, K., Risso, D., Fletcher, R.B., Das, D., Ngai, J., Yosef, N., Purdom, E.,
and Dudoit, S. (2018). Slingshot: cell lineage and pseudotime inference for sin-
gle-cell transcriptomics. BMC Genomics 19, 477.
Tailor, P., Tamura, T., Morse, H.C., 3rd, and Ozato, K. (2008). The BXH2 mu-
tation in IRF8 differentially impairs dendritic cell subset development in the
mouse. Blood 111, 1942–1945.
Thaventhiran, J.E.D., Lango Allen, H., Burren, O.S., Farmery, J.H.R., Staples,
E., Zhang, Z., Rae,W., Greene, D., Simeoni, I., Maimaris, J., et al. (2018).Whole
genome sequencing of primary immunodeficiency reveals a role for common
and rare variants in coding and non-coding sequences. bioRxiv. https://doi.
org/10.1101/499988.
Velten, L., Haas, S.F., Raffel, S., Blaszkiewicz, S., Islam, S., Hennig, B.P.,
Hirche, C., Lutz, C., Buss, E.C., Nowak, D., et al. (2017). Human haemato-
poietic stem cell lineage commitment is a continuous process. Nat. Cell Biol.
19, 271–281.
Villani, A.C., Satija, R., Reynolds, G., Sarkizova, S., Shekhar, K., Fletcher, J.,
Griesbeck, M., Butler, A., Zheng, S., Lazo, S., et al. (2017). Single-cell RNA-
seq reveals new types of human blood dendritic cells, monocytes, and pro-
genitors. Science 356, eaah4573.
Wilson, A., Murphy, M.J., Oskarsson, T., Kaloulis, K., Bettess, M.D., Oser,
G.M., Pasche, A.C., Knabenhans, C., Macdonald, H.R., and Trumpp, A.
(2004). c-Myc controls the balance between hematopoietic stem cell self-
renewal and differentiation. Genes Dev. 18, 2747–2763.
Yin, X., Yu, H., Jin, X., Li, J., Guo, H., Shi, Q., Yin, Z., Xu, Y., Wang, X., Liu, R.,
et al. (2017). Human blood CD1c+ dendritic cells encompass CD5high and
CD5low subsets that differ significantly in phenotype, gene expression, and
functions. J. Immunol. 198, 1553–1564.
ll
OPEN ACCESS Article
18 Immunity 53, 1–18, August 18, 2020
Please cite this article in press as: Cytlak et al., Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development
in Humans, Immunity (2020), https://doi.org/10.1016/j.immuni.2020.07.003
STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse anti-APC 176Yb, clone APC003 Fluidigm Cat# 3176007B
Mouse anti-human AXL APC, clone 108724 R&D Systems Cat# FAB154A
Mouse anti-human AXL purified, clone 108724 R&D Systems Cat# MAB154; RRID:AB_2062558
Mouse anti-human BTLA 163Dy, clone MIH26 Fluidigm Cat# 3163009B
Mouse anti-human BTLA BV650, clone J168-540 BD Biosciences Cat# 564803; RRID:AB_2738962
Mouse anti-human CD1c APC-Cy7, clone L161 BioLegend Cat# 331520; RRID:AB_10644008
Mouse anti-human CD1c PE-Cy7, clone L161 BioLegend Cat# 331516; RRID:AB_2275574
Mouse anti-human CD1c PerCP-Cy5.5, clone L161 BioLegend Cat# 331513; RRID:AB_1227536
Mouse anti-human CD1c purified, clone L161 BioLegend Cat# 331502; RRID:AB_1088995
Mouse anti-human CD2 151Eu, clone TS1/8 Fluidigm Cat# 3151003B
Mouse anti-human CD2 BV421, clone TS1/8 BioLegend Cat# 309217; RRID:AB_10915139
Mouse anti-human CD2 PE-CF594, clone RPA-2.10 BD Biosciences Cat# 562300; RRID:AB_11153492
Mouse anti-human CD3 AF700, clone SK7 (Leu-4) BioLegend Cat# 344822; RRID:AB_2563420
Mouse anti-human CD3 FITC, clone SK7(Leu-4) BD Biosciences Cat# 345763
Mouse anti-human CD3 PE, clone SK7(Leu9) BD Biosciences Cat# 345765
Mouse anti-human CD5 BUV737, clone UCHT2 BD Biosciences Cat# 564451; RRID:AB_2714177
Mouse anti-human CD5 purified, clone L17F12 BioLegend Cat# 364002; RRID:AB_2564477
Mouse anti-human CD7 FITC, clone Leu-9 BD Biosciences Cat# 347483; RRID:AB_400309
Mouse anti-human CD7 PE, clone M-T701 BD Biosciences Cat# 332774
Mouse anti-human CD10 156Gd, clone HI10a Fluidigm Cat# 3156001B
Mouse anti-human CD10 BV650, clone HI10a BD Biosciences Cat# 563734; RRID:AB_2738393
Mouse anti-human CD11b 144Nd, clone ICRF44 Fluidigm Cat# 3144001B
Mouse anti-human CD11c 159Tb, clone Bu15 Fluidigm Cat# 3159001B
Mouse anti-human CD11c AF700, clone B-ly6 BD Biosciences Cat# 561352; RRID:AB_10612006
Mouse anti-human CD11c APC-Cy7, clone Bu15 BioLegend Cat# 337218; RRID:AB_10662746
Mouse anti-human CD11c BV711, clone B-ly6 BioLegend Cat# 301630; RRID:AB_2562192
Mouse anti-human CD14 BV650, clone M5E2 BioLegend Cat# 301835; RRID:AB_11204241
Mouse anti-human CD14 FITC, clone M5E2 BD Biosciences Cat# 555397; RRID:AB_395798
Mouse anti-human CD14 PE, clone M5E2 BD Biosciences Cat# 555398; RRID:AB_395799
Mouse anti-human CD14 PE-Cy7, clone HCD14 BioLegend Cat# 325618; RRID:AB_830691
Mouse anti-human CD14 purified, clone M5E2 BioLegend Cat# 301802; RRID:AB_314184
Mouse anti-human CD15 164Dy, clone W6D3 Fluidigm Cat# 3164001B
Mouse anti-human CD15 BUV395, clone HI98 BD Biosciences Cat# 563872; RRID:AB_2738461
Mouse anti-human CD15 BV605, clone W6D3 BD Biosciences Cat# 562979; RRID:AB_2744292
Mouse anti-human CD16 209Bi, clone 3G8 Fluidigm Cat# 3209002B
Mouse anti-human CD16 AF700, clone 3G8 BioLegend Cat# 302026; RRID:AB_2278418
Mouse anti-human CD16 FITC, clone 3G8 BD Biosciences Cat# 335035
Mouse anti-human CD16 PE, clone 3G8 BD Biosciences Cat# 555407; RRID:AB_395807
Mouse anti-human CD16 PE-Dazzle594, clone 3G8 BioLegend Cat# 302054; RRID:AB_2563639
Mouse anti-human CD19 AF700, clone 4G7/HIB19 BioLegend Cat# 302226; RRID:AB_493751
Mouse anti-human CD19 FITC, clone 4G7 BD Biosciences Cat# 345776
Mouse anti-human CD19 PE, clone HIB19 BD Biosciences Cat# 555413; RRID:AB_395813
Mouse anti-human CD20 AF700, clone L27/2H7 BioLegend Cat# 302322; RRID:AB_493753
Mouse anti-human CD20 FITC, clone L27 BD Biosciences Cat# 345792
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Mouse anti-human CD20 PE, clone L27 BD Biosciences Cat# 345793
Mouse anti-human CD33 158Gd, clone WM53 Fluidigm Cat# 3158001B
Mouse anti-human CD33 APC, clone P67.6 BD Biosciences Cat# 345800
Mouse anti-human CD33 BV711, clone WM53 BD Biosciences Cat# 563171; RRID:AB_2738045
Mouse anti-human CD34 166Er, clone 581 Fluidigm Cat# 3166012B
Mouse anti-human CD34 APC-Cy7, clone 581 BioLegend Cat# 343514; RRID:AB_1877168
Mouse anti-human CD34 BV605, clone 581 BioLegend Cat# 343529; RRID:AB_2562193
Mouse anti-human CD34 FITC, clone 8G12 BD Biosciences Cat# 345801
Mouse anti-human CD34 PE-CF594, clone 581 BD Biosciences Cat# 562383; RRID:AB_11154586
Mouse anti-human CD36 155Gd, clone 5-271 Fluidigm Cat# 3155012B
Mouse anti-human CD38 PE-Cy7, clone HB7 BD Biosciences Cat# 335825
Mouse anti-human CD38 purified, clone HB-7 BioLegend Cat# 356602; RRID:AB_2561794
Mouse anti-human CD45 89Y, clone HI30 Fluidigm Cat# 3089003B
Mouse anti-human CD45 APC-Cy7, clone 2D1 BD Biosciences Cat# 557833; RRID:AB_396891
Mouse anti-human CD45 V450, clone 2D1 BD Biosciences Cat# 642275; RRID:AB_1645755
Mouse anti-human CD45RA 153Eu, clone HI100 Fluidigm Cat# 3153001B
Mouse anti-human CD45RA BV510, clone HI100 BioLegend Cat# 304142; RRID:AB_2561947
Rat anti-human CD52 PE, clone YTH34.5 Bio-Rad Cat# SFL1642PE; RRID:AB_324131
Mouse anti-human CD56 FITC, clone NCAM16.2 BD Biosciences Cat# 345811
Mouse anti-human CD88 PE, clone S5/1 BioLegend Cat# 344304; RRID:AB_2067175
Mouse anti-human CD88 purified, clone C5AR BioLegend Cat# 344302; RRID:AB_2259318
Mouse anti-human CD90 161Dy, clone 5E10 Fluidigm Cat# 3161009
Mouse anti-human CD90 AF700, clone 5E10 BioLegend Cat# 328120; RRID:AB_2203302
Mouse anti-human CD90 PerCP-Cy5.5, clone 5E10 BioLegend Cat# 328118; RRID:AB_2303335
Human anti-human CD100 APC-Vio770, clone REA316 Miltenyi Biotec Cat# 130-104-604; RRID:AB_2654328
Mouse anti-human CD100 purified, clone A8 BioLegend Cat# 328401; RRID:AB_1236386
Mouse anti-human CD115 purified, clone 9-4D2-1E4 BioLegend Cat# 347302; RRID:AB_2085375
Mouse anti-human CD116 BV421, clone hGMCSFR-M1 BD Biosciences Cat# 564045; RRID:AB_2738561
Mouse anti-human CD116 BV650, clone hGMCSFR-M1 BD Biosciences Cat# 564044; RRID:AB_2738560
Mouse anti-human CD116 purified, clone 4H1 BioLegend Cat# 305902; RRID:AB_314568
Mouse anti-human CD117 BV605, clone 104D2 BD Biosciences Cat# 562687; RRID:AB_2737721
Mouse anti-human CD117 PE, clone 104D2 BD Biosciences Cat# 332785
Mouse anti-human CD117 purified, clone 104D2 BioLegend Cat# 313201; RRID:AB_314980
Mouse anti-human CD123 143Nd, clone 6H6 Fluidigm Cat# 3143014B
Mouse anti-human CD123 BUV395, clone 7G3 BD Biosciences Cat# 564195; RRID:AB_2714171
Mouse anti-human CD123 BV421, clone 6H6 BioLegend Cat# 306018; RRID:AB_10962571
Mouse anti-human CD123 PerCP-Cy5.5, clone 7G3 BD Biosciences Cat# 558714; RRID:AB_1645547
Mouse anti-human CD135 BV711, clone 4G8 BD Biosciences Cat# 563908; RRID:AB_2738479
Mouse anti-human CD135 purified, clone BV10A4H2 BioLegend Cat# 313302; RRID:AB_314987
Mouse anti-human CD141 BV510, clone 1A4 BD Biosciences Cat# 563298; RRID:AB_2728103
Mouse anti-human CD141 purified, clone M80 BioLegend Cat# 344102; RRID:AB_2201808
Mouse anti-human CD161 PE-Cy7, clone HP-3G10 Thermo Fisher Scientific Cat# 25-1619-42; RRID:AB_10807086
Mouse anti-human CD303 147Sm, clone 201A Fluidigm Cat# 3147009B
Mouse anti-human CD303 APC, clone 201A BioLegend Cat# 354206; RRID:AB_11150412
Mouse anti-human CD303 BV605, clone 201A BioLegend Cat# 354224; RRID:AB_2572149
Mouse anti-human CD304 169Tm, clone 12C2 Fluidigm Cat# 3169018B
Mouse anti-human CD304 APC, clone 12C2 BioLegend Cat# 354506; RRID:AB_11219600
Mouse anti-human CD304 BV605, clone U21-1283 BD Biosciences Cat# 743130; RRID:AB_2741297
Mouse anti-human CLEC9A PE, clone 8F9 BioLegend Cat# 353804; RRID:AB_10965546
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Mouse anti-human CLEC9A purified, clone 8F9 BioLegend Cat# 353802; RRID:AB_10983070
Rat anti-human CX3CR1 APC, clone 2A9-1 BioLegend Cat# 341610; RRID:AB_2087424
Mouse anti-human FceRI 150Nd, clone AER-37 (CRA-1) Fluidigm Cat# 3150027B
Mouse anti-FITC purified, clone FIT-22 BioLegend Cat# 408305; RRID:AB_2563769
Mouse anti-human HLA-DR 173Yb, clone L243 Fluidigm Cat# 3173005B
Mouse anti-human HLA-DR AF700, clone G46-6 BD Biosciences Cat# 560743; RRID:AB_1727526
Mouse anti-human HLA-DR BV785, clone L243 BioLegend Cat# 307642; RRID:AB_2563461
Mouse anti-human HLA-DR PerCP-Cy5.5, clone L243 BioLegend Cat# 307629; RRID:AB_893575
Mouse anti-human ID2 purified, clone 4E12G5 Thermo Fisher Scientific Cat# MA5-17095; RRID:AB_2538566
Mouse anti-human IFN-a PE, clone LT27:295 Miltenyi Biotec Cat# 130-092-601; RRID:AB_871560
Rat anti-human IL-10 APC, clone JES3-9D7 BioLegend Cat# 501410; RRID:AB_315176
Mouse anti-human IL-12p40/p70 BV421, clone C8.6 BD Biosciences Cat# 565023; RRID:AB_2739045
Mouse anti-human IL-1b FITC, clone JK1B-1 BioLegend Cat# 508206; RRID:AB_345362
Mouse anti-human IL-8 PE-Cy7, clone E8N1 BioLegend Cat# 511416; RRID:AB_2565291
Rat anti-human IRF4 PE, clone 3E4 Thermo Fisher Scientific Cat# 12-9858-80; RRID:AB_10853179
Mouse anti-human IRF4 purified, clone IRF4.3E4 BioLegend Cat# 646402; RRID:AB_2280462
Mouse anti-human IRF8 efluor710, clone 3GYWCH Thermo Fisher Scientific Cat# 46-9852-80; RRID:AB_2573903
Mouse anti-human IRF8 purified, clone GW4CML3 Thermo Fisher Scientific Cat# 14-7888-82; RRID:AB_2572907
Goat anti-human KLF4 APC, clone POLY R&D Systems Cat# IC3640A; RRID:AB_2044690
Mouse anti-PE purified, clone PE001 BioLegend Cat# 408105; RRID:AB_2563787
Mouse anti-human SIGLEC-6 purified, clone 767329 R&D Systems Cat# MAB2859
Mouse anti-human SIRPA purified, clone 15-414 BioLegend Cat# 372102; RRID:AB_2629807
Mouse anti-human SIRPA/B AF700, clone SE5A5 BioLegend Cat# 323816; RRID:AB_2687275
Mouse anti-human SIRPA/B APC, clone SE5A5 BioLegend Cat# 323809; RRID:AB_11219399
Mouse anti-human SIRPA/B PE, clone SE5A5 BioLegend Cat# 323805; RRID:AB_830704
Mouse anti-human SLAN PE, clone DD1 Miltenyi Biotec Cat# 130-093-029; RRID:AB_871582
Biological Samples
Healthy human peripheral blood mononuclear
cells (PBMC)
Newcastle Biobank REC 12/NE/0395
Healthy human bone marrow mononuclear cells (BMMC) Newcastle Bone and Joint
Biobank and Project ethics
REC 14/NE/1212
REC 13/NE/1136
IRF8 patient tissues As previously described in
Hambleton et al. (2011) and
Bigley et al. (2018). Adult
material project specific.
Paediatric material through
Newcastle Biobank
REC 08/H0906/72
REC 16/NE/0002
Chemicals, Peptides, and Recombinant Proteins
Carboxyfluorescein succinimidyl ester (CFSE, final
concentration: 0.5 mM)
Invitrogen Cat# C34554
Lymphoprep density gradient solution Stem Cell Technologies Cat# 07851
Dulbecco’s phosphate-buffered saline (PBS) Sigma Cat# D8537-500ml
Fetal bovine serum, South American origin, batch 50115 Labtech Cat# FCS-SA/500
Ethylenediaminetetraacetic acid (EDTA) Sigma Cat# E7889
DAPI Partec Cat# D8417
Zombie UV Fixable Viability Kit Biolegend Cat# 423108
MEM Alpha Medium w/o Nucleosides (aMEM) Life Technologies Cat# 22561-021
RPMI-1640 Sigma Cat# R0883-500ml
L-Glutamine Sigma Cat#G7513-100ml
Penicillin-Streptomycin Sigma Cat# P0781
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REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant Human Stem Cell Factor (SCF) Immunotools Cat# 11343325
Recombinant human Granulocyte-Macrophage-Colony
Stimulating Factor (GM-CSF)
R&D systems Cat# CAA26822
Recombinant Human Flt-3 ligand Immunotools Cat# 11343305
IgG from mouse serum Sigma Cat# I5381
Triton X-100 Sigma Cat# 9002-93-1
Recombinant RNase inhibitor (2U/ml) Takara Clontech Cat# 2313B
polyinosinic:polycytidylic acid (poly(I:C), final
concentration: 10 mg/ml)
Invivogen Cat #tlrl-pic
Lipopolysaccharide (LPS, final concentration: 5ng/ml) Sigma Cat# L2654
CL075 (final concentration: 1 mg/ml) Invivogen Cat# tlrl-c75
CpG oligonucleotide (ODN 2216) (final
concentration: 7.5mM)
Invivogen Cat# tlrl-2216
Brefeldin A (final concentration: 10 mg/ml) Sigma Cat# B7651-5MG
Formaldehyde TAAB Laboratories Cat# F017/3
Cisplatin Fluidigm Cat# 201064
Irridium Fluidigm Cat# 201192A
EQ Four Element Calibration Beads Fluidigm Cat# 201078
Critical Commercial Assays
Foxp3 Transcription Factor Staining Buffer Set Thermo Fisher Scientific Cat# 00-5523
Maxpar antibody labeling kit Fluidigm N/A
Deposited Data
Single cell RNA sequencing data Human BM progenitors GSE142999 https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE142999
Single cell RNA sequencing data Human BM dendritic cells
and precursors
GSE143002 https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE143002
Single cell RNA sequencing data Human peripheral blood
CD123+ dendritic cell
precursors
GSE143158 https://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE143158
Experimental Models: Cell Lines
Mouse OP9 cell line ATCC CRL-2749
Software and Algorithms
FACSDIVA 8.0.1 or 8.0 software BD Biosciences N/A
FlowJo 10.5.3 Treestar, Inc N/A
CyTOF software v 6.7.1014 Fluidigm https://www.fluidigm.com/software
GraphPad Prism v5.0a GraphPad Software, Inc. N/A
Nanostring nSolver NanoString https://www.nanostring.com/products/
analysis-software/nsolver
Other
LSRFortessa X20 BD Biosciences H656385K01
FACS Aria Fusion Sorter BD Biosciences P656700000018
Helios CyTOF Fluidigm N/A
Greiner CELLSTAR 96 well plates Greiner M9436
Corning 96 Well TC-Treated Microplates size
96 wells, clear, polystyrene, round bottom, case of 50
(individually wrapped), sterile, lid
Corning CLS3799
50 mm sterile filter Sysmex Partec 04-004-2327
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RESOURCE AVAILABILITY
Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Venetia
Bigley (venetia.bigley@ncl.ac.uk)
Materials Availability
This study did not generate new unique reagents
Data and Code Availability
Single cell RNA-Seq datasets generated in this study are deposited in the Genome Expression Omnibus under the following acces-
sion numbers:
Human BM progenitors GSE142999
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE142999)
Human BM dendritic cells and precursors GSE143002
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143002)
Human PB dendritic cell precursors GSE143158
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE143158)
Subject Details
The study was performed in accordance with the Declaration of Helsinki. Written informed consent was obtained from participants or
their parents. The study was approved by local review board NRES Committee North East-Newcastle and North Tyneside: 08/
H0906/72 and REC 14/NE/1136; REC 14/NE/1212, 17/NE/0361.
Patients and healthy donors
Details of individuals carrying IRF8K108E/K108E and IRF8A83C/R291Q are previously described (Hambleton et al., 2011; Bigley et al.,
2018). The kindred carrying IRF8V426fs was identified through BRIDGE whole genome sequencing initiative (Ouwehand, 2019; Tha-
venthiran et al., 2018). Details and molecular characterization of the mutation will be published independently. Healthy bone marrow
was obtained from hematopoietic stem cell transplant donors (pediatric or adult) or from hip arthroplasty (adult).
METHOD DETAILS
Flow cytometry and cell sorting
Healthy control mononuclear cells from peripheral blood (PBMC) or bone marrow (BMMC), isolated by density centrifugation, were
stained in aliquots of 3 x106 cells/50 mL of Dulbecco’s phosphate-buffered saline (PBS) with 0.1%–2% fetal calf serum (FCS, GIBCO)
and 0.4% EDTA for 30min at room temperature (RT). Non-specific staining was blocked with 3 mL mouse IgG prior to staining. Dead
cells, usually < 5%, were excluded by DAPI (Partec) or Zombie (Biolegend) staining. Analysis was performed with a BD LSRFortessa
X20 and sortingwith a FACSAria Fusion Sorter (BDBiosciences) running BD FACSDIVA 8.0.1 or 8.0 software, respectively. Purity of >
98% was achieved in sorted populations. Data were processed with FlowJo 10.5.3 (Tree Star, Inc). Intracellular staining was per-
formed after surface staining, lysis and fixation (eBioscience) according to manufacturer’s instructions. Absolute cell counts were
obtained using TruCount tubes (BD Biosciences) with 200 mL whole blood and 900 mL of red cell lysis buffer added after staining.
For proliferation studies, BMMC were stained with carboxyfluorescein succinimidyl ester (CFSE, 0.5 mM, Invitrogen) prior to FACS
purification according to gating strategy in Figure 4A. and cultured in standard DC differentiation conditions. CFSE dilution was as-
sessed by flow cytometry on day 3. CD34+progenitors and CD14+monocytes were included as positive and negative controls,
respectively. A full list of antibodies is provided in the Key Resources Table.
In vitro generation of dendritic cells
FACS-purified human PB or BM CD34+ progenitors, progenitor subsets or pre-DC were cultured in 96 well U-bottomed plates
(Corning) with pre-seeded OP9 stromal cells (5000vwell) in 200 mL alpha-MEM (aMEM, GIBCO) supplemented with 1% penicillin/
streptomycin (Sigma), 10% FCS, 20ng/ml granulocyte-macrophage colony-stimulating factor (GM-CSF, R&D systems), 100ng/ml
Flt3-ligand (FLT3, Immunotools), 20ng/ml stem cell factor (SCF, Immunotools). CD34+ cells were seeded at 3000/well or 500/well
for serial time points. Pre-DC were seeded at 500-3000 cells/well, determined by the number of cells available after FACS-purifica-
tion. Half the volume of media, with cytokines, was replaced weekly. Cells were harvested on ice at day 14 or 21; or at days 3, 5, 7, 9,
11, 14 and 21 for serial time points, passed through a 50 mm filter (Sysmex Partec), washed in PBS, and stained for flow cytometric
analysis or FACS-purification.
Dendritic cell functional analysis
TLR stimulation: PBMC or in vitro generated cells were incubated in RPMI plus 10%FCS in the presence of polyinosinic:polycytidylic
acid (poly(I:C) (10 mg/ml, Invivogen), lipopolysaccharide (LPS) (5ng/ml, Sigma), CL075 (1 mg/ml, Invivogen) and CpG (7.5mM,
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Invivogen) for 14h at 37C, 5% CO2 with addition of Brefaldin A (10 mg/ml, eBioscience) after 3h. Dead cells (usually < 30%) were
excluded with Zombie amine dye (Biolegend). Intracellular cytokine staining was performed after surface staining, fixation and per-
meabilization (eBioscience) according to manufacturer’s instructions.
NanoString nCounter analysis
Dendritic cell subsets and monocytes were FACS-purified (> 98% purity) from ex vivo PBMC or cells generated from BM
CD34+progenitors after 21 days in culture and lysed in RLT buffer containing 1% b-mercaptoethanol at a concentration of 2000
cells/ml. Samples were analyzed on the NanoString nCounter platform using the Immunology V2 panel supplemented with 30
genes, as described in Kirkling et al. (2018).
Counts were normalized within the nSolver software (advanced analysis module version 1.1.4). The log2 transformed output data
were analyzed using R v 3.3.3. For principal component analysis (PCA), genes with normalized expression values below 16 in more
than half of the samples were removed (293/608 for ex vivo dataset and 288/608 for combined ex vivo and culture dataset). The re-
maining genes were used for the PC analyses.
A culture signature was derived by performing pairwise comparisons (two-tailed t test with Benjamini-Hochberg correction of
p values) of all culture versus all ex vivo populations. 110 genes with adjusted p values < 0.05 (the ‘culture signature’) were excluded
from further analysis. The remaining 210 genes were used to construct the combined ex vivo and culture-derived cell PCA plot.
Statistical computation of the signature genes for the blood CD1c+DC subsets andmonocytes was performedwith Bubble GUM, a
tool based on Gene Set Enrichment Analysis (GSEA) algorithm (Spinelli et al., 2015). Heatmaps were generated in R and display the
scaled expression of the top signature genes across the 5 blood and 3 cultured subsets. 129 signature genes with significant FDR
were identified for blood monocytes (top 32 based on fold change displayed on heatmap), 32 and 16 genes for CD14+DC3 and
CD5+DC2, respectively. No signature genes were identified for the CD14-BTLA-DC3 or CD5-BTLA+DC2 fractions.
Single cell RNA sequencing
Single human PBMC or BMMC were index-sorted into 96-well round-bottom plates
containing 2 mL cold RNA lysis buffer (RNase-free water, 2U/ml RNase inhibitor and 0.2%Triton X-100, Sigma) (three BMprogenitor
plates) or SMARTer Dilution buffer (SMARTer Kit, Fluidigm) with the addition of 2U/ml RNase inhibitor (three BM precursor plates and
one BM DC plate). Plates were immediately centrifugated at 500xg for 1 minute, frozen on dry ice then stored at 80oC. Each plate
included 2 controls; one blank and one well containing purified mouse RNA. The reverse transcription (RT) was performed using an
adapted Smart-Seq2 protocol (Picelli et al., 2014). Briefly, modifications included 21 PCR cycles and duplicate Ampure clean-up
steps, following cDNA generation. The library prep was performed using the Nextera XT DNA Library Prep Kit. The Illumina HiSeq
4000 platform was employed to generate paired-end reads (75bp x 2).
Alignment of reads to the human reference genome
reads were trimmed based on quality with Trimmomatic v 0.36 (Bolger et al., 2014). Bases with quality scores below Q10 (inferred
base cell accuracy below 90%) were trimmed and reads shorter than 60bp were dropped. The remaining reads were aligned in
the STAR mapping algorithm v 2.4.0 (Dobin and Gingeras, 2015) to the human reference genome version GRCh38.p7 (GENCODE
release 25) supplemented with External RNA Controls Consortium (ERCC) spike-in controls. The files were converted from SAM
format to the more compressed BAM format with SAMtools v 1.3 (Li et al., 2009).The count tables were obtained using HTSEQ v
0.6.1 (Anders et al., 2015). ENSEMBL IDs were converted to HGNC gene names using biomaRt v 2.30.0 (Durinck et al., 2005).
Gene and cell filtering
further analysis of the data was undertaken in R and Rstudio v 1.0.143. Quantitative details are documented in Table S3. The Scater R
package v 1.2.0 was used to perform cell and gene QC and filtering (McCarthy et al., 2017). To remove technical outlier genes with
poor coverage, only genes expressed at > 2 counts in > 2 cells were retained (range across datasets 14,458-18,791 genes). Low
quality cells were removed based on number of total features, total counts, percentage of counts derived from ERCC spike-ins
and % of mitochondrial gene counts (> 20%) (Table S3). After filtering, the number of cells remaining out of the total FACS sorted
for each dataset were: BMCD34+ progenitors, 262/399; BMCD34int pre- andmature DC, 244/260; PB pre-DC, 116/184. The normal-
ization was performed with the RUVg method (Risso et al., 2014) combined with counts per million (CPM) adjustment for library size
and log transformation [log2(CPM+1)] for all downstream analyses. Only the genes annotated as protein coding in the ‘‘gene_type’’
column of the GENCODE reference genome GTF file were retained. To minimize the effect of cell-division cycle on the clustering
performed in future steps, genes associated with cell cycle activity were downloaded from Macosko et al. (2015) and removed
from all our analyses. The number of protein-coding, non-cell cycle genes retained for each dataset were: BM CD34+ progenitors,
12406; BM CD34int pre- and mature DC, 12137; PB pre-DC, 10346 (Table S3).
Cell clustering
clustering was performed with all the protein-coding, non-cell cycle genes using the Single-Cell Consensus Clustering (SC3) R pack-
age v 1.3.18 (Kiselev et al., 2017). The SC3 tool requires the k number of number of clusters to be specified by the user. A range of
clusters (2 to 15) was visualized and interrogated for each of the datasets. The output from the ‘‘sc3_estimate_k’’ function guided the
minimum number of clusters to be considered for each of the datasets. Clustering solutions took into account cluster stability indices
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(‘average silhouette width’ > 0.45 and ‘stability index’ within SC3, detailed in Table S3), known cell phenotypes from index sorting
parameters, cluster marker genes defined in previous literature and minimum number of expected populations within the dataset.
Heatmaps with marker genes were generated within SC3. The area under the receiver operating characteristic curve (AUROC) and
p values assigned by a Wilcoxon signed rank test and corrected using the Holm method were used to define the marker genes
(thresholds for statistics are stated in figure legends and Table S3). Clusters were annotated based on the top statistically significant
marker genes from the SC3 output, and correlated with index-sorting phenotype and culture output.
tSNE analysis
the tSNE technique for dimensionality reduction was used to visualize the clusters. First, SC3 gene filter was applied to further remove
genes with low expression, and those ubiquitously expressed. The remaining genes (quantified for each dataset in Table S3) were
used for tSNE analysis with the Rtsne package v 0.13. An initial PCA step was introduced to reduce dimensionality and eliminate
noise. Top principal components accounting for most variance (25%–35%) were retained for the tSNE algorithm. The number of
PCs is stated in the relevant figure legends).
For the BM mature DC dataset, the DC2 and DC3 signatures were downloaded from Villani et al., 2017 (90 genes) (Villani et al.,
2017). 71 of the genes were identified in our dataset and used for SC3 clustering and tSNE analysis (Table S2), as described above.
For the signature scores displayed on tSNE embeddings or as a boxplot, the normalized counts for all genes present both in our
datasets and in the DC signatures identified in Villani et al., 2017 were rescaled from 0 to 1. The average scaled signature score was
then displayed on tSNE plots produced as described above. Graphics were generated with the ggplot2 package v 3.0.0.
Diffusion maps and lineage tracing
diffusion maps were used to infer a pseudo-temporal ordering and reconstruct lineage branching (Haghverdi et al., 2015). All protein
coding genes that were not known to play a role in cell cycle were used in the diffusion map calculation with the destiny tool v 2.14.0
(Angerer et al., 2016). An initial PCA step was employed to reduce noise, and PCs accounting for most variance (total of approxi-
mately 40% for both datasets) were retained for destiny. Diffusion components 1-3 were used for trajectory tracing with slingshot
v 1.2.0 (Street et al., 2018) and visualized on 3D plots. Graphics were generated with the rgl package v 0.100.19.
Helios Mass Cytometer (CyTOF) analysis
Pre-conjugated antibodies (Fluidigm), purified antibodies conjugated to their respective lanthanidemetals using theMaxpar antibody
labeling kit (as per manufacturer’s instructions; DVS Sciences) or fluorophore-conjugated primary with anti-fluorophore metal-con-
jugated secondary antibodies were used for surface or intracellular staining (Table S2; Key Resources Table).
Healthy control CD45+lineage- (CD3,19,20,56,161) PBMC (3x106 cells) or BMMC (1.5x 106) were FACS-purified into 1ml CyTOF
staining buffer (PBS plus 2%FCS). Cell staining was performed at room temperature in a final staining volume of 100ul. Centrifugation
was performed at 500xg for 5 minutes unless otherwise stated. ‘Barcoding’ of PBMC and BMMC samples was achieved by staining
with 0.5ug anti-CD45-Irr115 or anti-CD45-89Y, respectively, (30mins) in CyTOF staining buffer before washing twice in PBS. Bar-
coded PBMC and BMMC were combined before addition of 2.5 mM cisplatin for 5 minutes in PBS for live/dead cell discrimination,
then washed promptly in CyTOF staining buffer. Successive primary and secondary surface staining was performed using approx-
imately 0.5 mg of each antibody in CyTOF staining buffer (30mins) before washing twice with PBS. The cells were fixed in 500ml eBio-
science fixation buffer (eBioscience FoxP3 fix perm kit) with the addition of 500 mL of 3.2% formaldehyde (final concentration 1.6%)
and incubated for 30 minutes, before washing twice with eBioscience perm buffer. Cells were stained successively in perm buffer for
1hr each with intracellular primary and secondary antibodies then washed twice with PBS. Cells were resuspended in 500 mL 250nM
Irridium in PBS (final concentration 125nM) and 500 mL 3.2% formaldehyde (final concentration 1.6%) and incubated for 1hr, before
centrifugation and resuspension in 500 mL CyTOF wash buffer for overnight storage at 4C. Prior to CyTOF acquisition, cells were
washed twice in 200 mLMilliQ water (800xg for 8 minutes), counted, diluted to a maximum final concentration of 0.55x106/ml in MilliQ
water and filtered through a 40 mm filter (BD). EQ beads were added (10% by volume) and 1.5x106 cells were acquired on the Helios
mass cytometer running CyTOF software v 6.7.1014.
tSNE analysis
within the CyTOF software, the resultant flow cytometry file (.fcs) was normalized against the EQ bead signals and randomized for a
uniform negative distribution. FlowJo software was used to deconvolute live, lin(CD3,19,20,56)-HLA-DR+ PB or BM cells by manual
gating. For individual PB and BM DC and monocyte phenotyping analyses (Figure 1G), random sampling without replacement was
performed to select up to 2,300 CD141+Clec9A+ cDC1, 8,000 CD123+CD303+ pDC, 10,000 CD2+FCER1A+ CD1c+DC, 10,000
CD88+CD14+ monocytes and 4,000 CD88+CD16+ monocytes which were concatenated as a .fcs file and subjected to t-distributed
stochastic neighbor embedding (tSNE) dimension reduction with perplexity 15 from 1000 iterations, using CD markers 36, 11b, 123,
14, 5, 1c, 11c, 2, 141, 303, 304, 88, 123 and BTLA, AXL, SIGLEC6, IRF4, IRF8, FCER1A, SIRPA. Heat plots of marker expression
(ArcSinh scale, with cofactor of 5) on the reduced dimensions were generated within FlowJo.
For combined PB and BM progenitor, pre-DC, DC and monocyte analysis (Figures 5A–5F), combined lin-HLA-DR+ cells were
down-sampled to select 75,000 cells consisting of 20,000 CD11b+CD14+ monocytes, 4,000 CD11b+CD16+ monocytes and
50,000 non-monocyte cells. The concatenated .fcs file was subjected to tSNE dimension reduction with perplexity 30 from 1000
iterations using CDmarkers 14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 34, 88, 117, 1c, 5 and Clec9A, AXL, SIGLEC6,
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SIRPA, IRF4, IRF8, FCER1A, and BTLA. tSNE plots and marker expression heat plots were generated in ggplot2 R package using
tSNE co-ordinates exported from FlowJo.
Diffusion maps and lineage tracing
cells were down-sampled using random sampling within FlowJo, according to the gating strategy in Figures S5B and S5C, to select a
total of 14,000 cells consisting of up to 500 or 1000 cells per progenitor or precursor and mature cell population, respectively:
GMP33+(300), GMP33-(200), CD123lo-intGMP(298), CD123hi303/4lo(499), CD2+pDC(490), pDC(490), early pre-DC2(498), pre-
DC2(491), CD5-DC2(498), CD5+DC2(800), early pre-DC1(500), pre-DC1(254), cDC1(800), pre-DC3/mono(500), pre-DC3(298),
CD14-DC3(498), CD14+DC3(1000), pre-mono(500), mono(999). Further analysis was undertaken in R version 3.6.0. Diffusion map
calculation was performed with the destiny tool v 2.14.0 (Angerer et al., 2016) using log2-transformed values for the following CD
markers: 14, 16, 123, 11b, 116, 303, 304, 2, 38, 10, 33, 11c, 90, 141, 34, 88, 117, 1c, 5, 15 and Clec9A, AXL, SIGLEC6, SIRPA,
IRF4, IRF8, FCER1A, BTLA and FLT3. 3D graphics were produced with the rgl package v 0.100.30.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs were plotted and statistical analyses performed with Prism 8 (GraphPad software Inc) or in R v3.3.3. Replicate numbers,
p values and statistical tests are detailed in the figure legends.
ll
OPEN ACCESS Article
e8 Immunity 53, 1–18.e1–e8, August 18, 2020
Please cite this article in press as: Cytlak et al., Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development
in Humans, Immunity (2020), https://doi.org/10.1016/j.immuni.2020.07.003
